[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 791
1. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood; 2010 Apr 01;115(13):2578-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
  • Certain malignant B cells rely on B-cell receptor (BCR)-mediated survival signals.
  • In in vivo analyses of B-cell lymphoma cell lines and primary tumors, Syk inhibition induces apoptosis.
  • These data prompted a phase 1/2 clinical trial of fostamatinib disodium, the first clinically available oral Syk inhibitor, in patients with recurrent B-cell non-Hodgkin lymphoma (B-NHL).
  • Sixty-eight patients with recurrent B-NHL were then enrolled in 3 cohorts:.
  • (1) diffuse large B-cell lymphoma (DLBCL), (2) follicular lymphoma (FL), and (3) other NHL, including mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), mucosa-associated lymphoid tissue lymphoma, lymphoplasmacytic lymphomas, and small lymphocytic leukemia/chronic lymphocytic leukemia (SLL/CLL).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Oxazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyridines / therapeutic use

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Feb 15;356(7):741-2 [17301308.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2093-101 [17051243.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Jun 15;221(3):268-77 [17490694.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2230-7 [18006696.001]
  • [Cites] Blood. 2008 Aug 1;112(3):782-92 [18487510.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4579-86 [18662969.001]
  • [Cites] Arthritis Rheum. 2008 Nov;58(11):3309-18 [18975322.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):549-62 [19017179.001]
  • [Cites] Birth Defects Res A Clin Mol Teratol. 2009 Feb;85(2):130-6 [19107952.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2508-16 [18981293.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3050-8 [19074730.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3154-60 [19096013.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6153-60 [19369227.001]
  • [Cites] Blood. 2009 Jul 16;114(3):638-46 [19387007.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1029-37 [19491390.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3822-9 [19581539.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4156-62 [16912221.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Immunol Today. 2000 Mar;21(3):148-54 [10689303.001]
  • [Cites] J Immunol. 2000 Aug 1;165(3):1300-6 [10903730.001]
  • [Cites] Science. 2002 May 31;296(5573):1641-2 [12040177.001]
  • [Cites] J Allergy Clin Immunol. 2002 Sep;110(3):366-73 [12209081.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1057-69 [12453414.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Cell. 2004 Jun 11;117(6):787-800 [15186779.001]
  • [Cites] Mol Cell. 2004 Jun 18;14(6):696-7 [15200948.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1073-83 [9323135.001]
  • [Cites] Curr Opin Immunol. 1999 Apr;11(2):143-51 [10322153.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:329-34 [16304399.001]
  • [Cites] Br J Haematol. 2006 Feb;132(3):303-16 [16409295.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):283-94 [16557260.001]
  • [Cites] J Immunol. 2006 May 15;176(10):5715-9 [16670274.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3135-42 [16835385.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3428-33 [16888096.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008 [16946104.001]
  • [CommentIn] Blood. 2010 Apr 1;115(13):2561-2 [20360472.001]
  • (PMID = 19965662.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00446095
  • [Grant] United States / NCI NIH HHS / CA / P50 CA130805; United States / NCI NIH HHS / CA / CA-130805
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / Oxazines; 0 / Protein Kinase Inhibitors; 0 / Pyridines; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / SYK protein, human; EC 2.7.10.2 / Syk Kinase; SQ8A3S5101 / fostamatinib
  • [Other-IDs] NLM/ PMC2852362
  •  go-up   go-down


2. Dürr C, Pfeifer D, Claus R, Schmitt-Graeff A, Gerlach UV, Graeser R, Krüger S, Gerbitz A, Negrin RS, Finke J, Zeiser R: CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res; 2010 Dec 15;70(24):10170-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells.
  • Clinical studies indicate a role of allogeneic hematopoietic cell transplantation (alloHCT) for patients with refractory or recurrent B-cell lymphoma (BCL) indicative of a graft-versus-tumor effect.
  • Therefore, we studied Treg recruitment after alloHCT in different murine BCL models and the impact of lymphoma-derived chemoattractive signals.
  • CXCL12 production was dependent on antigen-presenting cells (APC) located in the lymphoma microenvironment, and their diphtheria-toxin receptor (DTR)-based depletion in CD11c.DTR-Tg mice significantly reduced Treg accumulation within BCL tissue.
  • [MeSH-major] Chemokine CXCL12 / immunology. Hematopoietic Stem Cell Transplantation. Lymphoma, B-Cell / immunology. Tumor Microenvironment / immunology

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 21159639.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CXCL12; 0 / Chemokines; 0 / Receptors, CXCR3; 0 / Receptors, CXCR4
  •  go-up   go-down


3. Ritz O, Guiter C, Castellano F, Dorsch K, Melzner J, Jais JP, Dubois G, Gaulard P, Möller P, Leroy K: Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood; 2009 Aug 6;114(6):1236-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.
  • Primary mediastinal B-cell lymphoma (PMBL) is a separate entity of aggressive B-cell lymphoma, characterized by a constitutive activation of janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway, also observed in Hodgkin lymphoma.
  • Here, we show that MedB-1 PMBL-derived and L1236 Hodgkin-derived cell lines and 20 of 55 (36%) PMBL cases harbor heterozygous missense mutations in STAT6 DNA binding domain, whereas no mutation was found in 25 diffuse large B-cell lymphoma samples.
  • Although the oncogenic properties of STAT6 mutant proteins remain to be determined, their recurrent selection in PMBL strongly argues for their involvement in the pathogenesis of this aggressive B-cell lymphoma.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Mediastinal Neoplasms / genetics. Mutation / genetics. Neoplasm Proteins / genetics. STAT6 Transcription Factor / genetics
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Male. Protein Structure, Tertiary / genetics. Signal Transduction / genetics

  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):393-401 [11241792.001]
  • [Cites] Blood. 2001 Jan 1;97(1):250-5 [11133768.001]
  • [Cites] Blood. 2002 Jan 15;99(2):618-26 [11781246.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):229-34 [12067685.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):489-95 [12478664.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2756-61 [12446450.001]
  • [Cites] J Immunol. 2003 Apr 1;170(7):3478-87 [12646608.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3271-5 [15126369.001]
  • [Cites] Blood. 2004 Jul 15;104(2):543-9 [15044251.001]
  • [Cites] Haematologica. 2004 Sep;89(9):1091-9 [15377470.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1571-8 [8608249.001]
  • [Cites] Cell. 1998 May 29;93(5):827-39 [9630226.001]
  • [Cites] Nature. 1998 Jul 9;394(6689):145-51 [9671298.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):178-87 [10029446.001]
  • [Cites] J Exp Med. 1999 Jun 21;189(12):1939-46 [10377189.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2535-42 [15572583.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2363-6 [16208407.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2470-3 [16269615.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2679-84 [16532038.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Jun;17(3):173-88 [16540365.001]
  • [Cites] Nat Rev Immunol. 2006 Aug;6(8):573-83 [16868548.001]
  • [Cites] PLoS Genet. 2006 Aug 18;2(8):e131 [16934001.001]
  • [Cites] Haematologica. 2007 Jul;92(7):913-20 [17606441.001]
  • [Cites] Nature. 2007 Aug 30;448(7157):1058-62 [17676033.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3387-90 [17652621.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4367-9 [17878403.001]
  • [Cites] Trends Biochem Sci. 2008 Mar;33(3):122-31 [18291658.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 [18765795.001]
  • [Cites] Leukemia. 2008 Nov;22(11):2106-10 [18401415.001]
  • [Cites] J Biol Chem. 2000 May 12;275(19):14255-9 [10747856.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):348-53 [11291070.001]
  • [CommentIn] Blood. 2009 Aug 6;114(6):1133-4 [19661272.001]
  • (PMID = 19423726.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / STAT6 Transcription Factor; 0 / STAT6 protein, human
  • [Other-IDs] NLM/ HALMS411059; NLM/ PMC2824656
  •  go-up   go-down


Advertisement
4. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A: Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol; 2008 Nov;143(3):355-60
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
  • Oblimersen sodium plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) patients.
  • Among the 20 patients with follicular lymphoma the ORR was 60% (eight CR, four PR).
  • Three of the responders were refractory to prior treatment with rituximab, and two of the responses occurred in patients who had failed an autologous stem cell transplant.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18764869.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / 01/CM17003
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Oligonucleotides, Antisense; 0 / Thionucleotides; 4F4X42SYQ6 / Rituximab; 85J5ZP6YSL / oblimersen
  •  go-up   go-down


5. Moore MM, Kovich OI, Brown LH: Primary cutaneous B-cell lymphoma (low-grade, non large cell). Dermatol Online J; 2007;13(1):8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous B-cell lymphoma (low-grade, non large cell).
  • A 43-year-old man presented with erythematous, indurated plaques on the scalp in the setting of a 16-year history of recurrent cutaneous tumors of the head and trunk.
  • Clinical and histopathologic findings were consistent with a diagnosis of primary cutaneous B-cell lymphoma.
  • Laboratory data and computed tomography imaging of the chest, abdomen, and pelvis failed to show an associated systemic lymphoma.
  • Primary cutaneous B-cell lymphomas are a heterogenous group of lymphomas that primarily involve the skin but have variable clinical, histopathologic, and immunologic phenotypes.
  • Rituximab, a chimeric monoclonal antibody that binds the B-cell-specific antigen CD20, has shown promise in treating a number of primary cutaneous B-cell lymphomas.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511941.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Papaliodis GN, Montezuma SR: Pseudo-hypopyon as the presenting feature of recurrent B-cell lymphoma. Ocul Immunol Inflamm; 2008 May-Jun;16(3):121-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudo-hypopyon as the presenting feature of recurrent B-cell lymphoma.
  • PURPOSE: To report a case of a pseudo-hypopyon as the presentation for recurrent B-cell lymphoma.
  • RESULTS: A 74-year-old man with past medical history of peripheral B-cell lymphoma developed a hypopyon 3 months after R-CHOP chemotherapy and prophylactic intrathecal chemotherapy.
  • Anterior chamber aspirate was consistent with B-cell lymphoma.
  • CONCLUSIONS: Pseudo-hypopyon as a manifestation of recurrent B-cell lymphoma is a rare clinical presentation of an intraocular malignancy.
  • [MeSH-major] Anterior Chamber. Eye Diseases / etiology. Lymphoma, B-Cell / complications

  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18569803.001).
  • [ISSN] 1744-5078
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


7. Lansigan F, Stearns DM, Foss F: Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Manag Res; 2010;2:53-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma.
  • Denileukin diftitox (Ontak(®)) is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare lymphoproliferative disorder of the skin.
  • CTCL is often a chronic progressive lymphoma requiring the sequential use of treatments such as retinoids, traditional chemotherapy, or biological response modifiers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21188096.001).
  • [ISSN] 1179-1322
  • [Journal-full-title] Cancer management and research
  • [ISO-abbreviation] Cancer Manag Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3004568
  • [Keywords] NOTNLM ; cutaneous T-cell lymphoma / denileukin diftitox / fusion protein toxin
  •  go-up   go-down


8. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG: Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol; 2009 Sep 10;27(26):4371-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
  • PURPOSE: To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics, and antitumor activity of dacetuzumab in patients with refractory or recurrent B-cell non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD40 / immunology. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / chemically induced. Antibodies, Monoclonal, Humanized. Cohort Studies. Cytokines / blood. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Fever / chemically induced. Headache / chemically induced. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Male. Middle Aged. Recurrence. Treatment Outcome. Young Adult

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19636010.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00103779
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD40; 0 / Cytokines; 0 / dacetuzumab
  •  go-up   go-down


9. Watson ME Jr, Storch GA: Recurrent Mycoplasma pneumoniae infection in a human immunodeficiency virus-positive child. Pediatr Infect Dis J; 2008 Nov;27(11):1037-8
Hazardous Substances Data Bank. AZITHROMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent Mycoplasma pneumoniae infection in a human immunodeficiency virus-positive child.
  • This report describes an HIV-positive female child with recurrent B-cell lymphoma and recurrent or relapsing pulmonary infections with M. Pneumoniae.
  • [MeSH-minor] Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Azithromycin / therapeutic use. Child. Doxycycline / therapeutic use. Fatal Outcome. Female. HIV Infections / drug therapy. Humans. Lymphoma, AIDS-Related / drug therapy. Mycoplasma pneumoniae / isolation & purification. Polymerase Chain Reaction. Recurrence. Sepsis. Zidovudine / therapeutic use

  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18985833.001).
  • [ISSN] 0891-3668
  • [Journal-full-title] The Pediatric infectious disease journal
  • [ISO-abbreviation] Pediatr. Infect. Dis. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 4B9XT59T7S / Zidovudine; 83905-01-5 / Azithromycin; N12000U13O / Doxycycline
  •  go-up   go-down


10. Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM: Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol; 2005 Aug 1;23(22):5044-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
  • PURPOSE: To explore the safety and therapeutic activity of combination anti-B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Twenty-three patients with recurrent B-cell lymphoma received anti-CD22 epratuzumab 360 mg/m(2) and anti-CD20 rituximab 375 mg/m(2) monoclonal antibodies weekly for four doses each.
  • Sixteen patients had indolent histologies (15 with follicular lymphoma) and seven had aggressive NHL (all diffuse large B-cell lymphoma [DLBCL]).
  • Indolent patients had received a median of one (range, one to six) prior treatment, with 31% refractory to their last therapy and 81% with high-risk Follicular Lymphoma International Prognostic Index scores.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15955901.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR16814
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / epratuzumab; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


11. Huang Q, Wilczynski SP, Chang KL, Weiss LM: Composite recurrent hodgkin lymphoma and diffuse large B-cell lymphoma: one clone, two faces. Am J Clin Pathol; 2006 Aug;126(2):222-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite recurrent hodgkin lymphoma and diffuse large B-cell lymphoma: one clone, two faces.
  • We describe a composite lymphoma with recurrent Hodgkin lymphoma and diffuse large B-cell lymphoma components manifesting as a single, perforated small intestinal tumor in a 56-year-old man with a history of classical Hodgkin lymphoma and recent relapse in the bone marrow.
  • The resected mass had 2 morphologically and immunophenotypically distinct components; 1 showed a pleomorphic cellular infiltrate with fibrosis and contained numerous, large Hodgkin/Reed-Sternberg-like cells and variants.
  • The adjacent component displayed sheets of relatively uniform, large lymphoid cells with typical morphologic features of diffuse large cell lymphoma.
  • The tumor cells showed uniform expression of tested B-cell antigens, absence of CD30 or CD15, and complete absence of EBV-encoded RNA.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Recurrence, Local. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891197.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Viral
  •  go-up   go-down


12. Inoue D, Kimura T, Shimoji S, Mori M, Nagai Y, Tabata S, Kurata M, Matsushita A, Nagai K, Maruoka H, Yamashita E, Takahashi T: [Angioimmunoblastic T-cell lymphoma complicated by recurrent drug-induced agranulocytosis]. Rinsho Ketsueki; 2009 Feb;50(2):87-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma complicated by recurrent drug-induced agranulocytosis].
  • Hematologic examination demonstrated a white blood cell count of 1,400/microl with 0% neutrophils, and 18% abnormal lymphocytes.
  • Based on the histologic findings, PCR, and immunohistologic analyses, he was diagnosed with angioimmunoblastic T cell lymphoma (AILT) in leukemic state.
  • The response of the lymphoma to conventional chemotherapy (CHOP and ESHAP) was poor.
  • The treatment resulted in a partial remission of AILT including disappearance of circulating lymphoma cells.
  • [MeSH-major] Acetaminophen / adverse effects. Agranulocytosis / chemically induced. Analgesics, Non-Narcotic / adverse effects. Immunoblastic Lymphadenopathy / etiology. Lymphoma, T-Cell / etiology

  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19265300.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 0 / Immunosuppressive Agents; 362O9ITL9D / Acetaminophen; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


13. Pandya VB, Conway RM, Taylor SF: Primary cutaneous B cell lymphoma presenting as recurrent eyelid swelling. Clin Exp Ophthalmol; 2008 Oct;36(7):672-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous B cell lymphoma presenting as recurrent eyelid swelling.
  • Primary cutaneous lymphoma represents a distinct clinical entity within the spectrum of haematological malignancy.
  • A case of primary cutaneous B cell lymphoma is reported, presenting in an 87-year-old female with a 2-year history of intermittent swelling and discolouration of the right upper and lower eyelids, in the absence of systemic symptoms.
  • Histopathological examination of an incision biopsy revealed a lymphoid infiltrate in the dermis with immunophenotypic features of B cell lymphoma.
  • Ophthalmologists should include primary cutaneous lymphoma in the differential diagnosis of recurrent eyelid swelling.
  • [MeSH-major] Edema / pathology. Eyelid Neoplasms / pathology. Eyelids / pathology. Lymphoma, B-Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983553.001).
  • [ISSN] 1442-9071
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


14. Park B, Kim W, Eom H, Kim J, Oh S, Suh C: A phase II trial of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for patients with refractory or relapsed non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8559

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for patients with refractory or relapsed non-Hodgkin's lymphoma.
  • : 8559 Background: Gemcitabine combined with cisplatin has been known as an effective regimen for lymphoma treatment in salvage setting.
  • We investigated the response rate and toxicity of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOx) for recurrent or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), looking for the more effective and less toxic therapy.
  • METHODS: Patients with recurrent or refractory diffuse large B-cell NHL or mantle cell lymphoma, measurable disease, and more than one previous chemotherapy regimen were eligible.
  • Patients could then proceed to stem cell transplantation (SCT) or receive up to six treatment cycles.
  • The median age of the patients was 54 years (range, 18-75 years) and most had diffuse large-cell lymphoma.
  • CONCLUSIONS: GIDOx is an active salvage regimen in aggressive B-cell NHL and can be administered with acceptable toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960992.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Dummer R, Hymes K, Sterry W, Steinhoff M, Assaf C, Kerl H, Ahern J, Rizvi S, Ricker JL, Whittaker S: Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: A phase I study. J Clin Oncol; 2009 May 20;27(15_suppl):8572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: A phase I study.
  • : 8572 Background: Vorinostat, a histone deacetylase inhibitor, is registered for the treatment of advanced cutaneous T-cell lymphoma (CTCL) in the US.
  • METHODS: Eligible pts were aged ≥18 years with stage ≥IB progressive, persistent, or recurrent CTCL refractory to ≥1 systemic therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961018.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Jajeh A: Reccurent and prolonged panctopenia with rituximab therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e19550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This drug has been implemented in the treatment of B cell lymphoproliferative disorders as well as non-neoplastic disease such as autoimmune thrombocytopenia, immune hemolytic anemia and other disorders related to overexpression of antibodies against the host.
  • This abstract reports recurrent and long standing pancytopenia that had adverse deadly sequellae.
  • METHODS: This abstract report five cases of recurrent and prolonged pancytopenia not related to concomittant cytotoxic effect of chemotherapy.
  • RESULTS: Five patient sustained recurrent prolonged pancytopenia post rituximab therapy.
  • One patient, a female( age 33) had rheumatoid arthritis and the rest had non hodgekin's lymphoma.
  • None of the patients with non hodgkin's lymphoma had bone marrow involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961092.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ruan J, Martin P, Coleman M, Furman R, Glynn P, Joyce M, Cheung K, Shore T, Schuster M, Leonard J: Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma (MCL). J Clin Oncol; 2009 May 20;27(15_suppl):8525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma (MCL).
  • : 8525 Background: Targeting tumor microenvironment and angiogenesis is a novel therapeutic strategy in lymphoma.
  • We report phase II safety, activity, and angiogenic profiling data with the novel combination RT-PEPC in elderly patients with recurrent MCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960902.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Hentrich M, Gerl A, Lutz L, Karthaus M, Schiel X: Unexpected toxicity (UT) and opportunistic infections (OI) after rituximab-containing therapy for non-Hodgkin's lymphoma (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):e19546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected toxicity (UT) and opportunistic infections (OI) after rituximab-containing therapy for non-Hodgkin's lymphoma (NHL).
  • UT consisted of interstitial pneumonitis (IP) in 2 pts after 8 and 6 cycles of R-CHOP for diffuse large cell lymphoma (DLCL), a case of congestive heart failure (NYHA III°) after 6x R-CHOP + 2x R-M for follicular lymphoma (FL) and a case of grade 4 pancytopenia lasting for 22 days following 2x R-FC for chronic lymphocytic leukemia.
  • OI consisted of pneumocystis jirovecii pneumonia after 5x R-CHOP-14 for DLCL, Epstein-Barr-virus (EBV)-associated hepatitis after 5x R-CHOP-21 for relapsed FL and generalized herpes zoster following 6x R-bendamustine (RB) + 1x R-M for recurrent BALT-lymphoma.
  • Moreover, 2 pts were transferred to us for therapy of enterovirus-induced encephalitis after 6x R-CHOP-21 + 2x R-M for FL (n=1) and cerebral toxoplasmosis in a pt heavily pretreated with R-containing therapy for relapsed mantle cell lymphoma (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Yavuz S, Erkisi M, Petekkaya I, Basel N: Important serum markers in malignant lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e22225

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Important serum markers in malignant lymphoma.
  • : e22225 Background: In this study, 78 patients with new diagnosed, 21 patients with relapsed malignant lymphoma who applied to Cukurova University Hospital between March 2006 - 2008, and 36 age and sex matched healthy control group were evaluated and have been followed up.
  • After the chemotherapy (CT), CD20 (+) cell percentage decreased significantly only in new diagnosed patients (p<0.001).
  • Pretreatment CD20 (+) cell levels were higher in responding patients than no responders (15.
  • Peripheral blood CD <sub>4</sub> (+) cell levels were below the healthy control group (p= 0.01) and remained low after the CT.
  • Interestingly, CD8 (+) cell levels increased in responders, after the CT (p= 0.046) in both patient groups.
  • Serum prealbumine levels were lower in lymphoma patients than the healthy controls (p< 0.001).
  • Its level was increased after treatment, especially in patients with recurrent disease (21.15± 5.89 versus 26.60 ± 7.29 mg/dl, p= 0.019).
  • CONCLUSIONS: In conclusion, it was decided that; during the different stages of lymphoma progression, several mutations may occur, in the different components of the host immune system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964089.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Rizvi S, Lis J, Boileau K, Garcia-Vargas J: Incidence of thromboembolism in patients receiving vorinostat: Clinical trial and post-marketing data from more than 1,800 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e14547

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vorinostat, a histone deacetylase inhibitor, has been licensed in the USA for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following two systemic therapies.
  • A committee of independent (non-Merck employees) academic experts evaluated these reports.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963621.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Castro JE, Sandoval-Sus JD, Melo-Cardenas J, Darrah D, Urquiza M, Pakbaz RS, Prussak CE, Kipps TJ: Phase I study of intranodal direct injection of adenovirus encoding recombinant CD40-ligand (Ad-ISF35) in patients with chronic lymphocytic leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):3003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3003 Background: Transduction of chronic lymphocytic leukemia (CLL) cells with replication-defective adenovirus (Ad) encoding a genetically engineered, membrane-stablized CD154 (ISF35) converts transduced, and "bystander" non-transduced, CLL cells into proficient antigen presenting cells that can induce immunity against autologous leukemia cells.
  • Preclinical studies demonstrated that direct injection of Ad-ISF35 into lymphoma nodules can induce potent anti-lymphoma immune responses in test animals, capable of eradicating lethal tumors at distal sites and protect against recurrent disease upon subsequent re-challenge with syngeneic tumor.
  • Importantly, IDI of Ad-ISF35 resulted in significant reductions in blood leukemia cell counts and a median reduction of 53.2% (range 25-75.4%) in the size of lymph nodes and/or spleen, which was durable (≥ 4 months) in 9 pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962049.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gribbin TE, Senzer N, Raizer JJ, Shen S, Nabors LB, Wiranowska M, Fiveash JB: A phase I evaluation of intravenous (IV) &lt;sup&gt;131&lt;/sup&gt;I-chlorotoxin delivery to solid peripheral and intracranial tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e14507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report imaging and safety data from a Phase I clinical trial in patients with recurrent metastatic somatic and/or cerebral solid tumors that received IV <sup>131</sup>I-TM601.
  • Tumor-specific uptake was observed in patients with malignant glioma (7/8), metastatic melanoma (7/7), non-small cell lung cancer (3/4), colon cancer (6/7), pancreatic cancer (2/3), prostate cancer (2/2), breast cancer (1/4) and in one evaluable patient each with transitional cell carcinoma, pleomorphic xanthoastrocytoma and metastatic paraganglioma.
  • No uptake was seen in CNS lymphoma (n=1), ovarian (n=2), small cell lung (n=2), or medulllary thyroid cancers (n=1).
  • Based on normal tissue dosimetry from this study, future clinical trials will evaluate safety and therapeutic efficacy in patients with recurrent glioma and metastatic melanoma at doses up to 100 mCi <sup>131</sup>I-TM601 (maximum single dose).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963538.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Kim Y, Beynon J: Effect of dosing cycles on safety of denileukin diftitox (Dd) in cutaneous T-cell lymphoma (CTCL) patients: Integrated analysis of three phase III studies. J Clin Oncol; 2009 May 20;27(15_suppl):e19557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of dosing cycles on safety of denileukin diftitox (Dd) in cutaneous T-cell lymphoma (CTCL) patients: Integrated analysis of three phase III studies.
  • : e19557 Background: Dd is a novel IL-2 receptor-targeted recombinant fusion protein that is approved for treatment of persistent/recurrent CTCL expressing CD25.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961073.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Acosta M, Duvic M, Lopez-Anaya A: Relationship between efficacy of denileukin diftitox (Dd) and antibody development in cutaneous T-cell lymphoma (CTCL): An analysis of two phase III studies. J Clin Oncol; 2009 May 20;27(15_suppl):e19534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between efficacy of denileukin diftitox (Dd) and antibody development in cutaneous T-cell lymphoma (CTCL): An analysis of two phase III studies.
  • : e19534 Background: Dd is a novel IL-2 receptor-targeted recombinant fusion protein approved for persistent/recurrent CTCL expressing CD25.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961028.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Dang NH, Sun Y, Gao J: Effect of dose on denileukin diftitox (Dd) response in treatment-naïve cutaneous T-cell lymphoma (CTCL) subjects: A retrospective analysis of three phase III studies. J Clin Oncol; 2009 May 20;27(15_suppl):e19509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of dose on denileukin diftitox (Dd) response in treatment-naïve cutaneous T-cell lymphoma (CTCL) subjects: A retrospective analysis of three phase III studies.
  • Dd is approved for the treatment of persistent/recurrent CD25(+) CTCL and is the most extensively studied agent in CTCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960866.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Giaccone G, Rajan A, Carter C, Kelly R, Berman A, Spittler J, Espinoza-Delgado I, Lee M, Trepel J, Loehrer P: Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):7589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is no established role of second-line therapy in patients with refractory or recurrent disease.
  • Belinostat is an HDAC inhibitor with activity in cutaneous and peripheral T cell lymphoma and is being investigated in several solid tumors.
  • METHODS: Patients with recurrent thymoma or thymic carcinoma, progressing after platinum-based chemotherapy were eligible.
  • Belinostat has activity in patients with recurrent or refractory thymoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963413.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Bartlett N, Forero-Torres A, Rosenblatt J, Fanale M, Horning SJ, Thompson S, Sievers EL, Kennedy DA: Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). J Clin Oncol; 2009 May 20;27(15_suppl):8500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL).
  • SGN-35 causes cell cycle arrest and apoptosis by binding to CD30 on the tumor cell surface, internalizing, and releasing MMAE into the cell.
  • METHODS: To assess if more frequent dosing might maximize anti-tumor activity with acceptable tolerability, a multicenter, phase 1, weekly dosing, dose-escalation study (3+3 design) was conducted in pts with refractory or recurrent HL or sALCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960851.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Sumrall A, Herrin V: Recurrent, transformed non-Hodgkin's lymphoma presenting as chiasmal syndrome with hyperprolactinemia and hypopituitarism. J Miss State Med Assoc; 2010 Feb;51(2):35-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent, transformed non-Hodgkin's lymphoma presenting as chiasmal syndrome with hyperprolactinemia and hypopituitarism.
  • A 69-year-old white female with past medical history of follicular cell lymphoma presented to her local physician with new neurological findings.
  • She was subsequently diagnosed with a pituitary lesion comprised of diffuse large B cell lymphoma.
  • Non-Hodgkin's lymphoma (NHL) affecting the pituitary uncommonly appears as metastatic disease from a concurrent systemic lymphoma.
  • This case represents the first case of recurrent, transformed NHL as chiasmal syndrome with hyperprolactinemia and hypopituitarism in the American medical literature.
  • [MeSH-major] Hyperprolactinemia. Hypopituitarism. Lymphoma, Large B-Cell, Diffuse. Optic Chiasm. Pituitary Neoplasms


29. Dijkman R, Tensen CP, Jordanova ES, Knijnenburg J, Hoefnagel JJ, Mulder AA, Rosenberg C, Raap AK, Willemze R, Szuhai K, Vermeer MH: Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol; 2006 Jan 10;24(2):296-305
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma.
  • PURPOSE: To evaluate the clinical relevance of genomic aberrations in primary cutaneous large B-cell lymphoma (PCLBCL).
  • PATIENTS AND METHODS: Skin biopsy samples of 31 patients with a PCLBCL classified as either primary cutaneous follicle center lymphoma (PCFCL; n = 19) or PCLBCL, leg type (n = 12), according to the WHO-European Organisation for Research and Treatment of Cancer (EORTC) classification, were investigated using array-based comparative genomic hybridization, fluorescence in situ hybridization (FISH), and examination of promoter hypermethylation.
  • RESULTS: The most recurrent alterations in PCFCL were high-level DNA amplifications at 2p16.1 (63%) and deletion of chromosome 14q32.33 (68%).
  • Seven of seven PCLBCL, leg type, patients with deletion of 9p21.3 and/or complete methylation of CDKN2A died as a result of their lymphoma.
  • [MeSH-major] Chromosome Aberrations. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330669.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15
  •  go-up   go-down


30. Andersen CL, Gruszka-Westwood A, Atkinson S, Matutes E, Catovsky D, Pedersen RK, Pedersen BB, Pulczynski S, Hokland P, Jacobsen E, Koch J: Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization. Cancer Genet Cytogenet; 2005 Jan 15;156(2):122-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization.
  • The cytogenetics of splenic marginal zone lymphoma (SMZL) is less well characterized than the cytogenetics of other non-Hodgkin B-cell lymphomas.
  • [MeSH-major] Chromosome Aberrations. Lymphoma, B-Cell / genetics. Splenic Neoplasms / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642391.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


31. Jetsrisuparb A, Wiangnon S, Komvilaisak P, Kularbkaew C, Yutanawiboonchai W, Mairieng E: Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's lymphoma. J Pediatr Hematol Oncol; 2005 Apr;27(4):223-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's lymphoma.
  • This report is the first to describe the successful treatment of a 14-year-old boy with aggressive recurrent, CD20-positive, B-cell large cell non-Hodgkin's lymphoma.
  • Rituximab and CHOP in addition to chemotherapy may be an alternative treatment for aggressive recurrent, pediatric CD20-positive B-cell large cell non-Hodgkin's lymphoma if highly intensive chemotherapy and stem cell transplantation are not available.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838396.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


32. Dorrepaal SJ, Margolin EA, Wang C: Bilateral pseudohypopyon as a presenting feature of recurrent diffuse large B-cell lymphoma. J Neuroophthalmol; 2010 Mar;30(1):67-9
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral pseudohypopyon as a presenting feature of recurrent diffuse large B-cell lymphoma.
  • A 55-year-old man with Gaucher disease and B-cell lymphoma developed a white meniscus along the inferior portion of the anterior chamber of both eyes.
  • Aspiration of aqueous fluid confirmed that the meniscus was made up of lymphoma cells, indicating that it was a pseudohypopyon. (A true hypopyon is made up of reactive white blood cells.
  • This is the first report of binocular pseudohypopyon confirmed as lymphomatous by flow cytometric immunophenotyping analysis in a patient with diffuse large B-cell lymphoma.
  • [MeSH-major] Anterior Chamber / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20182212.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Cho-Vega JH, Vega F, Rassidakis G, Medeiros LJ: Primary cutaneous marginal zone B-cell lymphoma. Am J Clin Pathol; 2006 Jun;125 Suppl:S38-49
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous marginal zone B-cell lymphoma.
  • Primary cutaneous marginal zone B-cell lymphoma (PCMZL) is included as one of the major types of primary cutaneous B-cell lymphoma in the revised World Health Organization-European Organization for Research and Treatment of Cancer classification.
  • The neoplastic cells express B-cell markers and usually bcl-2 and are negative for CD5, CD10, and bcl-6.
  • Approximately 10% to 20% of PCMZLs have recurrent chromosomal translocations, including the t(14;18)(q32;q21)/IgH-malt1, t(11;18)(q21;q21), and t(3;14)(p14;q32).
  • [MeSH-major] Lymphoma, B-Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16830956.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 87
  •  go-up   go-down


34. Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM: The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol; 2005 Oct;32(9):616-21
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
  • BACKGROUND: Rituximab has been used to treat relapsed low-grade or advanced non-Hodgkin's lymphoma since 1997, targeting the CD20 antigen expressed by B cells.
  • METHODS: Four patients with CD20-positive cutaneous B-cell lymphoma received rituximab therapy with subsequent recurrences.
  • CONCLUSIONS: Rituximab may be associated with the emergence of CD20-negative B-cell clones, potentially rendering a tumor insensitive to this drug.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / metabolism. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Neoplasm Recurrence, Local / metabolism. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16176299.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


35. Davies AJ, Rosenwald A, Wright G, Lee A, Last KW, Weisenburger DD, Chan WC, Delabie J, Braziel RM, Campo E, Gascoyne RD, Jaffe ES, Muller-Hermelink K, Ott G, Calaminici M, Norton AJ, Goff LK, Fitzgibbon J, Staudt LM, Andrew Lister T: Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol; 2007 Jan;136(2):286-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms.
  • This study was undertaken to further elucidate the biological mechanisms underlying the frequent event of transformation of follicular lymphoma (FL) to diffuse large B-cell lymphoma (t-FL).
  • Transformed follicular lymphoma was predominantly of the germinal centre B-like phenotype both at the mRNA and protein level.
  • This group was associated with the presence of recurrent oncogenic abnormalities.
  • Genes involved in cellular proliferation prevailed amongst those that were significantly increased upon transformation and T cell and follicular dendritic-associated genes predominated amongst those that decreased. t-FL is a germinal centre B (GCB)-like malignancy that evolves by two pathways, one that is similar in proliferation rate to the antecedent FL and the other that has a higher proliferation rate and is characterised by the presence of recognised oncogenic abnormalities.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 15;95(2):651-9 [10627476.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):1017-24 [10702417.001]
  • [Cites] Blood. 2000 Jul 15;96(2):635-9 [10887128.001]
  • [Cites] Br J Haematol. 2000 Nov;111(2):618-25 [11122110.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2142-8 [11187904.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):727-35 [11157024.001]
  • [Cites] Br J Cancer. 2001 Feb;84(4):499-503 [11207045.001]
  • [Cites] Oncogene. 2001 Mar 1;20(9):1103-9 [11314047.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):202-8 [11328303.001]
  • [Cites] Immunity. 2001 Sep;15(3):375-85 [11567628.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):7610-8 [11751859.001]
  • [Cites] Prostate. 2002 Apr 1;51(1):59-72 [11920959.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8886-91 [12077300.001]
  • [Cites] Lab Invest. 2003 Feb;83(2):271-85 [12594241.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):185-97 [12620412.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3109-17 [12406872.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7259-64 [12756297.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1443-8 [12738680.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Hum Pathol. 2003 Sep;34(9):915-23 [14562288.001]
  • [Cites] Bioinformatics. 2003 Dec 12;19(18):2448-55 [14668230.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Br J Haematol. 2004 Feb;124(3):325-8 [14717779.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Jun;4(3):449-57 [15161443.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Cancer. 1979 Aug;44(2):645-51 [383259.001]
  • [Cites] Cancer Treat Rep. 1981 May-Jun;65(5-6):413-8 [7016324.001]
  • [Cites] Blood. 1982 Feb;59(2):258-64 [7034812.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):393-8 [6344979.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1527-32 [1875216.001]
  • [Cites] Science. 1992 May 8;256(5058):827-30 [1589764.001]
  • [Cites] Blood. 1992 Aug 1;80(3):758-67 [1638027.001]
  • [Cites] Blood. 1993 Oct 1;82(7):1994-2004 [8400252.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2289-95 [8400281.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1587-94 [9193357.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 2:119-22 [9209654.001]
  • [Cites] Blood. 1998 Jan 1;91(1):331-9 [9414302.001]
  • [Cites] Oncogene. 1998 Jan 8;16(1):69-76 [9467944.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4677-85 [9616165.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4765-9 [10519380.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):891-9 [15516961.001]
  • [Cites] Blood. 2005 Jan 1;105(1):301-7 [15345589.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4643-51 [15837966.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1459-65 [15902285.001]
  • (PMID = 17278262.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA114778-01; United States / NCI NIH HHS / CA / U01 CA114778-01; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS39595; NLM/ PMC2532951
  •  go-up   go-down


36. Li S: Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity. Int J Clin Exp Pathol; 2009;2(6):508-18
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity.
  • Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK(+) LBCL) represents a distinct subtype of mature B-cell neoplasms in the most recent WHO classification of hematolymphoid neoplasms.
  • It has a characteristic immunoblastic/plasmablastic morphology, a distinct immunophenotypic profile and recurrent cytogenetic/molecular genetic abnormalities, and has been reported in both the adult and pediatric populations.
  • With the advent of new ALK inhibitors for possible targeted therapy clinical trials, it is important to recognize this new entity, particularly in the pediatric population because the prognosis is worse than the more common ALK+ anaplastic large cell lymphoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2009 Feb;174(2):361-70 [19131589.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2642-4 [12816858.001]
  • [Cites] Hum Pathol. 2009 Jan;40(1):75-82 [18755494.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):930-5 [18724359.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):975-8 [18923525.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):971-4 [18923524.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):967-70 [18923523.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):108-13 [18220322.001]
  • [Cites] Med Res Rev. 2008 May;28(3):372-412 [17694547.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):13-7 [18166835.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22 [18089725.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):11-23 [18097461.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):940-5 [17509395.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4408-17 [17483355.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):770-8 [17439836.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):310-9 [17277765.001]
  • [Cites] Histopathology. 2007 Jan;50(2):278-82 [17222259.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5 [17185414.001]
  • [Cites] Tumori. 2006 Sep-Oct;92(5):449-51 [17168442.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3275-9 [17094440.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(16):6209-22 [16880530.001]
  • [Cites] Gene Expr Patterns. 2006 Jun;6(5):448-61 [16458083.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):649-53 [15852431.001]
  • [Cites] Rinsho Ketsueki. 2005 Jul;46(7):501-6 [16440742.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):390-1 [16086416.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1839-40 [16107887.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3191-6 [16101126.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1128-34 [15902287.001]
  • [Cites] Pol J Pathol. 2005;56(1):37-45 [15921012.001]
  • [Cites] Am J Surg Pathol. 2004 Dec;28(12):1609-14 [15577680.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2776-80 [10383129.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1954-60 [7655022.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1285-8 [15492998.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2568-73 [12763927.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2638-41 [12750159.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):828-32 [12920229.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1919-27 [12424201.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Aug;34(4):354-62 [12112524.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1364-71 [11684952.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):411-5 [11485898.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):569-76 [11406658.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12):9526-31 [11121404.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1711-21 [10793082.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7750-61 [14586401.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20852-7 [19088198.001]
  • (PMID = 19636398.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2713458
  • [Keywords] NOTNLM ; ALK / Anaplastic lymphoma kinase / CLTC/ALK / diffuse large B-cell lymphoma / t(2;17)
  •  go-up   go-down


37. Massone C, Basso M, Rongioletti F: Cutaneous presentation of recurrence of lymphoepithelioid T-cell lymphoma (Lennert's lymphoma). Clin Exp Dermatol; 2005 Mar;30(2):155-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous presentation of recurrence of lymphoepithelioid T-cell lymphoma (Lennert's lymphoma).
  • Lennert's lymphoma (LL) is a T-cell lymphoma characterized by the presence of atypical T lymphocytes, admixed with histiocytes and epithelioid granulomas.
  • We report a female patient who presented with papules and nodules on the trunk and upper limbs as the first manifestation of recurrent LL.
  • [MeSH-major] Lymphoma, T-Cell / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725244.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Matsuo T, Ichimura K, Okada H, Shinagawa K, Fukushima K, Okano M, Otsuka M, Yoshino T: Clonal analysis of bilateral, recurrent, or systemically multifocal ocular adnexal lymphoma. J Clin Exp Hematop; 2010;50(1):27-38
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal analysis of bilateral, recurrent, or systemically multifocal ocular adnexal lymphoma.
  • The purpose of this study is to determine the same or different clonality between bilateral or recurrent lesions, or between or among ocular adnexal lesions and systemically multifocal lesions in 10 consecutive patients with ocular adnexal lymphoma : 8 had extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) and 2 had mantle cell lymphoma, observed from 1995 to 2008 at Okayama University Hospital.
  • A discrete DNA fragment was generated by polymerase chain reaction amplification of the immunoglobulin heavy chain gene from all samples except for two samples of bilateral orbital mantle cell lymphoma lesions and one sample of the scalp skin MALT lymphoma lesion.
  • The size of DNA fragments were the same between bilateral orbital or conjunctival lesions of 5 patients, between original and recurrent conjunctival lesions of one patient, between the orbital lesion and the oral cavity lesion in one patient, and among bilateral orbital lesions, buccal, rectum, and stomach lesions of one patient.
  • Sequencing of the DNA fragments showed the same sequence between bilateral or recurrent or multifocal lesions in 8 patients except for one : the bilateral orbital lesions, rectum, and stomach lesions shared the same sequence while the buccal lesion had one nucleotide difference compared to the sequence shared by the other 4 lesions.
  • In conclusion, bilateral, recurrent, or systemically multifocal lesions of ocular adnexal lymphoma shared the clonality between or among the lesions.
  • [MeSH-major] Eye Neoplasms / genetics. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell, Marginal Zone / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505273.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


39. Haque SA, Shad A, Ozdemirli M, Shanmugam VK, Kallakury B: A thirteen year old female with primary T-cell rich B-cell lymphoma of bone masquerading as chronic recurrent multifocal osteomyelitis. Pediatr Rep; 2009;1(1):e3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A thirteen year old female with primary T-cell rich B-cell lymphoma of bone masquerading as chronic recurrent multifocal osteomyelitis.
  • Primary lymphoma of the bone (PLB) accounts for 2% of all non-Hodgkin's lymphomas, and until recently it had not been well characterized in literature.
  • In this case, the initial presentation, with migratory large joint polyarthralgias and bone pain, mimicked chronic recurrent multifocal osteomyelitis (CRMO).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Feb;16(1):200-2 [18315931.001]
  • [Cites] Korean J Intern Med. 2002 Sep;17(3):191-7 [12298430.001]
  • [Cites] Rheumatology (Oxford). 2007 Jan;46(1):154-60 [16782988.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):47-54 [17145622.001]
  • [Cites] Jpn J Clin Oncol. 2007 Mar;37(3):216-23 [17472971.001]
  • [Cites] Clin Orthop Relat Res. 2007 Sep;462:11-9 [17496555.001]
  • [Cites] Can Assoc Radiol J. 1989 Apr;40(2):75-9 [2702504.001]
  • (PMID = 21589819.001).
  • [ISSN] 2036-749X
  • [Journal-full-title] Pediatric reports
  • [ISO-abbreviation] Pediatr Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3096024
  • [Keywords] NOTNLM ; adolescent. / bone pain / chronic recurrent multifocal osteomyelitis / primary lymphoma of bone
  •  go-up   go-down


40. Murota H, Shoda Y, Ishibashi T, Sugahara H, Matsumura I, Katayama I: Improvement of recurrent urticaria in a patient with Schnitzler syndrome associated with B-cell lymphoma with combination rituximab and radiotherapy. J Am Acad Dermatol; 2009 Dec;61(6):1070-5
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of recurrent urticaria in a patient with Schnitzler syndrome associated with B-cell lymphoma with combination rituximab and radiotherapy.
  • Schnitzler syndrome can precede the onset of a true lymphoproliferative disorder including Waldenström macroglobulinemia and rarely systemic marginal zone B-cell lymphoma.
  • An evaluation for malignancy using systemic computed tomography scan and fluorodeoxyglucose positron emission tomography revealed the retroperitoneal tumor, and a subsequent bone-marrow aspirate confirmed the diagnosis of B-cell lymphoma.
  • This case indicates that a detailed search for malignant neoplasms might be required for the long-term management of Schnitzler syndrome, and that B-cell lymphomas may contribute to the pathogenesis of this condition.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Retroperitoneal Neoplasms / radiotherapy. Schnitzler Syndrome / complications. Urticaria / complications

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hives.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632739.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


41. Agathocleous A, Rohatiner A, Rule S, Hunter H, Kerr JP, Neeson SM, Matthews J, Strauss S, Montoto S, Johnson P, Radford J, Lister A: Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. Br J Haematol; 2010 Nov;151(4):346-53
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
  • The combination of bortezomib and rituximab was evaluated in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL) and Waldenström macroglobulinaemia (WM), in a Phase I and later, a randomized Phase II study.
  • In the randomized study, 42 patients with recurrent/refractory disease received either: bortezomib 1·3 mg/m(2) on days 1, 4, 8 and 11 of a 3-week cycle with rituximab 375 mg/m(2) on day 1 (21 patients) or: bortezomib 1·6 mg/m(2) and rituximab on days 1, 8, 15 and 22 of a 5-week cycle (with rituximab being given only in cycles 1 and 4).Twenty-eight patients were withdrawn (toxicity 16, progression 7, and 'patient choice' 5).
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antibodies, Monoclonal, Murine-Derived / adverse effects. Boronic Acids / administration & dosage. Boronic Acids / adverse effects. Bortezomib. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Hematologic Diseases / chemically induced. Humans. Lymphoma, Follicular / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Male. Middle Aged. Pyrazines / administration & dosage. Pyrazines / adverse effects. Rituximab. Survival Analysis. Treatment Outcome. Waldenstrom Macroglobulinemia / drug therapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20880120.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Boronic Acids; 0 / Pyrazines; 4F4X42SYQ6 / Rituximab; 69G8BD63PP / Bortezomib
  •  go-up   go-down


42. Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V, Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire: Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol; 2008 May 20;26(15):2512-8
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
  • PURPOSE: The prognosis of relapsing primary CNS lymphoma (PCNSL) is poor.
  • We report the results of a prospective multicenter trial of intensive chemotherapy followed by autologous hematopoietic stem-cell rescue (IC + HCR) in immunocompetent adult patients with PCNSL or intraocular lymphoma (IOL) after failure of high-dose methotrexate-based treatment.
  • CONCLUSION: IC + HCR is an effective treatment for refractory and recurrent PCNSL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Eye Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413641.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


43. Verma S, Frambach GE, Seilstad KH, Nuovo G, Porcu P, Magro CM: Epstein--Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin. J Cutan Pathol; 2005 Aug;32(7):474-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein--Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin.
  • BACKGROUND: Epstein-Barr virus (EBV) has been implicated in B-cell lymphoma associated with iatrogenic immune dysregulation, primarily in the context of extracutaneous lymphoma.
  • METHODS: We describe six patients, five transplant recipients receiving cyclosporine and one patient with rheumatoid arthritis receiving methotrexate, who developed cutaneous presentations of EBV-associated B-cell lymphoma.
  • RESULTS: The cases comprised plasmablastic lymphoma (one case), plasmacytic marginal zone lymphoma (two cases), and diffuse large B-cell lymphoma (three cases).
  • Recurrent disease developed in two, with one patient succumbing to multiorgan dissemination.
  • CONCLUSIONS: EBV-associated cutaneous B-cell lymphoma is characterized by a long interval between the initiation of immunosuppression and the development of lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / isolation & purification. Immunocompromised Host. Lymphoma, B-Cell / immunology. Skin Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008691.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Messenger; 0 / RNA, Viral; EC 2.7.1.21 / Thymidine Kinase
  •  go-up   go-down


44. Bo LJ, Liang AB, Liu B, Chen YH, Wang F, Jin XP: [Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma]. Ai Zheng; 2006 Dec;25(12):1553-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: There is no standard salvage regimen for patients with recurrent and refractory non-Hodgkin's lymphoma (NHL) so far.
  • This study was to investigate the efficacy of DICE (dexamethasone, isofosfamide, cisplatin, and etoposide) regimen on recurrent and refractory NHL, and observe the adverse events.
  • METHODS: Clinical records of 80 patients with recurrent and refractory NHL, who failed to get remission from CHOP regimen (cyclophosfamide, vincristine, and donaurubicin) and accepted DICE as a salvage regimen for 6 cycles, were reviewed.
  • Of the 80 patients, 25 were T-cell original, and the other 55 were B-cell original.
  • The complete remission (CR) rate was 27.5%.The total response rate was 48.0% for T-cell NHL and 60.0% for B-cell NHL.
  • The CR rate was 16.0% for T-cell NHL and 32.7% for B-cell NHL.
  • CONCLUSION: DICE regimen is effective in treating recurrent and refractory NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alopecia / chemically induced. Cisplatin / adverse effects. Cisplatin / therapeutic use. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / adverse effects. Ifosfamide / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Male. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Remission Induction. Thrombocytopenia / chemically induced. Young Adult

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17166385.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; DICE protocol
  •  go-up   go-down


45. Hicks D, Mick A: Recurrent subconjunctival hemorrhages leading to the discovery of ocular adnexal lymphoma. Optometry; 2010 Oct;81(10):528-32
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent subconjunctival hemorrhages leading to the discovery of ocular adnexal lymphoma.
  • This report details a case in which persistent subconjunctival hemorrhages led to the discovery of ocular adnexal lymphoma.
  • CASE REPORT: A 68-year-old white man presented with a 7- to 8-month history of a recurrent red left eye.
  • The signs, symptoms, incidence, pathophysiology, treatment, and prognosis of ocular adnexal lymphoma are also discussed.
  • Although not typical, the first sign in this case was a recurrent subconjunctival hemorrhage.
  • [MeSH-major] Conjunctival Diseases / etiology. Eye Hemorrhage / etiology. Eye Neoplasms / complications. Lymphoma, B-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20705524.001).
  • [ISSN] 1558-1527
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Zettl A, deLeeuw R, Haralambieva E, Mueller-Hermelink HK: Enteropathy-type T-cell lymphoma. Am J Clin Pathol; 2007 May;127(5):701-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enteropathy-type T-cell lymphoma.
  • Session 7 of the Society for Hematopathology/European Association for Haematopathology Workshop was devoted to case presentations and discussion of enteropathy-type T-cell lymphoma (ETL) and other T-cell lymphomas involving the gastrointestinal tract.
  • ETL is a rare type of T-cell lymphoma, often associated with a history of celiac disease, that usually arises in the jejunum but can involve other gastrointestinal tract sites (eg, stomach and colon).
  • Comparative genomic hybridization has shown recurrent chromosomal gains and losses that are characteristic of ETL and uncommon in other T-cell lymphomas, providing useful ancillary data for the diagnosis of ETL.
  • [MeSH-major] Intestinal Neoplasms / pathology. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511112.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56
  • [Number-of-references] 19
  •  go-up   go-down


47. Wallet N, Ghez D, Delarue R, Suarez F, Rubio MT, Fischer A, Canioni D, Varet B, Hermine O: Diffuse large B-cell lymphoma in hyperimmunoglobulinemia E syndrome. Clin Lymphoma Myeloma; 2007 May;7(6):425-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma in hyperimmunoglobulinemia E syndrome.
  • We report a case of diffuse large B-cell lymphoma occurring in a patient with the hyperimmunoglobulinemia E syndrome, a rare immune disorder defined by elevated immunoglobulin E levels and recurrent bacterial and fungal infections often manifesting as cold abscesses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Job Syndrome / complications. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621409.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 37341-29-0 / Immunoglobulin E; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


48. Heyning FH, Jansen PM, Hogendoorn PC, Szuhai K: Array-based comparative genomic hybridisation analysis reveals recurrent chromosomal alterations in primary diffuse large B cell lymphoma of bone. J Clin Pathol; 2010 Dec;63(12):1095-100
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array-based comparative genomic hybridisation analysis reveals recurrent chromosomal alterations in primary diffuse large B cell lymphoma of bone.
  • AIMS: Primary non-Hodgkin's lymphoma of bone (PLB) is a rare subtype of primary extranodal diffuse large B cell lymphoma.
  • Here the authors performed the first array-CGH study to detect illness related genomic alterations in nine, clinically well-staged primary lymphoma of bone cases.
  • METHODS: Nine frozen samples from primary lymphoma of bone patients were immunophenotyped and subsequently investigated using a well-established array-CGH platform.
  • RESULTS: Of the nine patients, eight reached complete remission, and one had progressive disease and died of primary lymphoma of bone.
  • CONCLUSIONS: The authors found several recurrent genomic aberrations, including five cases with gain of 1q and four cases with 2p16.1 amplification.
  • These findings further substantiate the notion that primary lymphoma of bone should be considered as a distinct entity not only on clinic-pathological grounds but also on the genomic level as well.
  • [MeSH-major] Bone Neoplasms / genetics. Chromosome Aberrations. Lymphoma, Large B-Cell, Diffuse / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20962053.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Yiannias JA, DiCaudo DJ, Maskin E: Peripheral T-cell lymphoma presenting as lipoatrophy and nodules. Int J Dermatol; 2006 Dec;45(12):1415-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma presenting as lipoatrophy and nodules.
  • Lymphoma presents rarely with a constellation of nodules, panniculitis, and localized lipoatrophy.
  • The histopathologic similarities of lymphoma and connective tissue disease panniculitis may create a diagnostic challenge.
  • METHODS: We retrospectively reviewed the case of a 47-year-old man who presented 15 years earlier with recurrent fevers, fatigue, tender subcutaneous nodules, and facial, trunk, and extremity lipoatrophy.
  • Biopsy of a new chin nodule indicated peripheral T-cell lymphoma, whereas an evaluation for systemic malignant involvement was negative.
  • CONCLUSIONS: We report a rare case of lymphoma presenting as nodules and profound lipoatrophy, which exemplifies the complexity of lymphomas.
  • Profound lipoatrophy and panniculitis may be an unusual and diagnostically challenging presentation of cutaneous lymphoma.
  • [MeSH-major] Lipodystrophy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Panniculitis, Lupus Erythematosus / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184242.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Seto M: Genomic profiles in B cell lymphoma. Int J Hematol; 2010 Sep;92(2):238-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiles in B cell lymphoma.
  • Chromosome translocations found in B cell lymphomas generate typical genome profiles that are characteristic of each disease entity.
  • The mechanisms of lymphomagenesis have been investigated with respect to the involvement of deregulated genes in tumor development, as characterized by the promotion of cell proliferation and the blockage of cell differentiation and anti-apoptosis.
  • New technology such as array CGH and expression profiling introduced as a result of the human genome project introduced a new paradigm from which to understand the molecular mechanisms of lymphoma development.
  • Analyses with this new technology revealed that genome profiles of disease entities are characteristic and differ from disease to disease, although the genome profile of each patient with the same disease entity varies significantly given the recurrent genetic alterations frequently found.
  • Based on these findings, the future prospect and direction of lymphoma research will be discussed.
  • [MeSH-major] Lymphoma, B-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]
  • [Cites] Science. 1983 Nov 18;222(4625):765-71 [6356357.001]
  • [Cites] Blood. 2009 Sep 17;114(12 ):2467-75 [19608751.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):1-7 [17886247.001]
  • [Cites] Jpn J Cancer Res. 1994 Sep;85(9):918-26 [7961120.001]
  • [Cites] Nature. 1988 Nov 17;336(6196):259-61 [2848196.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):399-407 [9408757.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3944-8 [9307277.001]
  • [Cites] Leukemia. 2001 Jan;15(1):148-56 [11243383.001]
  • [Cites] Int J Cancer. 1976 Jan 15;17(1):47-56 [946170.001]
  • [Cites] Cell. 1984 Jan;36(1):93-9 [6319012.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Aug;46(8):776-83 [17492759.001]
  • [Cites] Haematologica. 2009 Jan;94(1):61-9 [19029149.001]
  • [Cites] Immunity. 2003 Nov;19(5):749-58 [14614861.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4148-52 [8364907.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jun;86(12):4589-93 [2543982.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]
  • [Cites] Nature. 1991 Jan 17;349(6306):254-6 [1987477.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Nov;44(3):247-55 [16049916.001]
  • [Cites] Nature. 1989 Nov 9;342(6246):195-8 [2478890.001]
  • [Cites] Cancer Res. 1979 Aug;39(8):3119-28 [582296.001]
  • [Cites] Nature. 2008 Nov 6;456(7218):66-72 [18987736.001]
  • [Cites] Oncogene. 1999 Oct 14;18(42):5785-94 [10523859.001]
  • [Cites] Int J Cancer. 1978 Jul 15;22(1):14-21 [355152.001]
  • [Cites] J Clin Invest. 1987 Nov;80(5):1512-5 [3500184.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):704-10 [15471554.001]
  • [Cites] Nat Med. 2008 Feb;14(2):144-53 [18223655.001]
  • [Cites] N Engl J Med. 2009 Sep 10;361(11):1058-66 [19657110.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):440-2 [3262202.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5948-55 [15342373.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):533-8 [3906410.001]
  • [Cites] Jpn J Cancer Res. 1995 Sep;86(9):890-8 [7591969.001]
  • [Cites] J Cell Biol. 2009 Nov 2;187(3):429-42 [19948485.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1226-31 [8049438.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4500-7 [16484591.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):30-8 [19118030.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] Oncogene. 1992 Jul;7(7):1401-6 [1535701.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(14):5214-8 [3523487.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1076-81 [18948948.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1770-7 [15886317.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2253-61 [10733493.001]
  • [Cites] Cell. 1986 Oct 10;47(1):19-28 [2875799.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12 ):1348-58 [17115033.001]
  • [Cites] Blood. 2001 Jul 15;98(2):486-8 [11435322.001]
  • [Cites] Nature. 1983 Nov 17-23;306(5940):239-42 [6316147.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1348-58 [15608680.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):19012-9 [11262391.001]
  • [Cites] Blood. 1995 May 1;85(9):2528-36 [7727781.001]
  • [Cites] Cancer Sci. 2010 Mar;101(3):573-8 [20070305.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3087-95 [15126345.001]
  • [Cites] Nature. 1991 Apr 11;350(6318):512-5 [1826542.001]
  • [Cites] Cell. 2001 Jan 12;104(1):33-42 [11163238.001]
  • [Cites] EMBO J. 1988 Jan;7(1):123-31 [2834197.001]
  • (PMID = 20799004.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  •  go-up   go-down


51. Küppers R: The biology of Hodgkin's lymphoma. Nat Rev Cancer; 2009 Jan;9(1):15-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The biology of Hodgkin's lymphoma.
  • Hodgkin's lymphoma was first described in 1832.
  • The aetiology of this lymphoma, however, remained enigmatic for a long time.
  • Only within the past 10 years has the B-cell nature of the pathognomonic Hodgkin and Reed-Sternberg (HRS) cells been revealed, along with several recurrent genetic lesions.
  • HRS cells in classical Hodgkin's lymphoma have several characteristics that are unusual for lymphoid tumour cells, and the Hodgkin's lymphoma microenvironment is dominated by an extensive mixed, potentially inflammatory cellular infiltrate.
  • [MeSH-major] Hodgkin Disease / etiology
  • [MeSH-minor] B-Lymphocytes / pathology. B-Lymphocytes / virology. Cell Dedifferentiation / genetics. Cell Transformation, Viral. Epstein-Barr Virus Infections / pathology. Gene Expression Regulation, Neoplastic. Germinal Center / pathology. Herpesvirus 4, Human / pathogenicity. Humans. Inflammation. Intercellular Signaling Peptides and Proteins / physiology. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Reed-Sternberg Cells / pathology. Signal Transduction. Transcription Factors / physiology. Tumor Escape. Viral Proteins / physiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19078975.001).
  • [ISSN] 1474-1768
  • [Journal-full-title] Nature reviews. Cancer
  • [ISO-abbreviation] Nat. Rev. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / Transcription Factors; 0 / Viral Proteins
  • [Number-of-references] 164
  •  go-up   go-down


52. Fukuhara N, Tagawa H, Kameoka Y, Kasugai Y, Karnan S, Kameoka J, Sasaki T, Morishima Y, Nakamura S, Seto M: Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma. Cancer Sci; 2006 Jun;97(6):499-504
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma.
  • Amplification of 2p has been observed as a recurrent alteration in diffuse large B-cell lymphoma (DLBCL).
  • All of these 25 cases included recurrent copy number gain at 2p15-16.
  • [MeSH-major] Chromosomes, Human, Pair 2 / genetics. Gene Amplification. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734728.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


53. Reichard KK, Hall BK, Corn A, Foucar MK, Hozier J: Automated analysis of fluorescence in situ hybridization on fixed, paraffin-embedded whole tissue sections in B-cell lymphoma. Mod Pathol; 2006 Aug;19(8):1027-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automated analysis of fluorescence in situ hybridization on fixed, paraffin-embedded whole tissue sections in B-cell lymphoma.
  • Certain recurrent cytogenetic abnormalities are diagnostic of a specific neoplasm and may portend prognosis.
  • Three probe sets were analyzed on archival specimens with a confirmed diagnosis of mantle cell lymphoma, follicular lymphoma or Burkitt lymphoma.
  • 100% of mantle cell lymphomas (7/7) were positive for t(11;14), 91% of follicular lymphomas (10/11) for t(14;18) and 100% of Burkitt lymphomas (9/9) for t(8;14).
  • Based on these results, automated analysis of fluorescence in situ hybridization on fixed tissues is accurate and valuable in the evaluation of B-cell lymphoma, and may provide pertinent diagnostic and prognostic information.
  • [MeSH-major] Image Processing, Computer-Assisted / methods. In Situ Hybridization, Fluorescence / methods. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Burkitt Lymphoma / genetics. Burkitt Lymphoma / pathology. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Chromosomes, Human, Pair 8. Humans. Lymph Nodes / pathology. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / pathology. Paraffin Embedding. Prognosis. Tissue Fixation. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680153.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Ishikawa M, Watabe H, Hayakawa M, Yoshitomi T: Peripheral T-cell lymphoma of the eyelid. Clin Ophthalmol; 2009;3:527-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma of the eyelid.
  • PURPOSE: To report a case of a 25-year-old woman with previously treated peripheral T-cell lymphoma (PTCL) presenting with a recurrent lower eyelid lesion.
  • CONCLUSIONS: Although lymphoma isolated to the ocular adnexa is rare, it should always be included in the differential diagnosis of any patient presenting with progressive swelling of the eyelid or ocular region.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cutis. 1996 Jun;57(6):437-40 [8804850.001]
  • [Cites] Ophthalmology. 1990 Oct;97(10):1352-7 [2243687.001]
  • [Cites] Mayo Clin Proc. 1989 Aug;64(8):940-4 [2796404.001]
  • [Cites] Ophthalmology. 1999 Jul;106(7):1339-44 [10406618.001]
  • [Cites] Arch Ophthalmol. 1981 Feb;99(2):272-7 [7469864.001]
  • [Cites] Jpn J Ophthalmol. 2006 Jul-Aug;50(4):388-90 [16897229.001]
  • [Cites] Can J Ophthalmol. 2005 Aug;40(4):467-8 [16116511.001]
  • [Cites] Ophthalmology. 1985 Sep;92(9):1288-93 [3877264.001]
  • (PMID = 19789662.001).
  • [ISSN] 1177-5467
  • [Journal-full-title] Clinical ophthalmology (Auckland, N.Z.)
  • [ISO-abbreviation] Clin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2754084
  • [Keywords] NOTNLM ; chalazion / eyelid / peripheral T-cell lymphoma
  •  go-up   go-down


55. Kimm LR, deLeeuw RJ, Savage KJ, Rosenwald A, Campo E, Delabie J, Ott G, Muller-Hermelink HK, Jaffe ES, Rimsza LM, Weisenburger DD, Chan WC, Staudt LM, Connors JM, Gascoyne RD, Lam WL: Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. Genes Chromosomes Cancer; 2007 Dec;46(12):1090-7
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent occurrence of deletions in primary mediastinal B-cell lymphoma.
  • Primary mediastinal B-cell lymphoma (PMBCL) is a distinct subtype of diffuse large B-cell lymphoma.
  • This finding contrasts many other types of lymphoma, in which deletions are common.
  • Recurrent gains were detected at all previously reported regions of gain, including 9p seen in approximately 70% of cases.
  • Recurrent chromosomal losses were observed at 1p, 3p, 4q, 6q, 7p, and 17p, with a novel event at 1p13.1-p13.2 representing the most frequent at 42% of cases analyzed.
  • [MeSH-major] Chromosome Deletion. Lymphoma, Large B-Cell, Diffuse / genetics. Mediastinal Neoplasms / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17823928.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


56. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A; 2008 Sep 9;105(36):13520-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
  • Gene-expression profiling has been used to define 3 molecular subtypes of diffuse large B-cell lymphoma (DLBCL), termed germinal center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, and primary mediastinal B-cell lymphoma (PMBL).
  • Of 272 recurrent chromosomal aberrations that were associated with gene-expression alterations, 30 were used differentially by the DLBCL subtypes (P < 0.006).
  • Knockdown of SPIB by RNA interference was toxic to ABC DLBCL cell lines but not to GCB DLBCL, PMBL, or myeloma cell lines, strongly implicating SPIB as an oncogene involved in the pathogenesis of ABC DLBCL.
  • In GCB DLBCL, amplification of the oncogenic mir-17-92 microRNA cluster and deletion of the tumor suppressor PTEN were recurrent, but these events did not occur in ABC DLBCL.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30 [15983384.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Adv Immunol. 2005;87:163-208 [16102574.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1770-7 [15886317.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3087-95 [15126345.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72 [15199222.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] EMBO J. 1997 Dec 1;16(23):7118-29 [9384589.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4487-9 [9882102.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):549-52 [10676635.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):325-34 [11555708.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):920-32 [12461565.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):28-40 [15671525.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7444-51 [15618216.001]
  • [Cites] Leukemia. 2005 Apr;19(4):652-8 [15703784.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2477-85 [16317097.001]
  • [Cites] Nature. 2006 May 4;441(7089):106-10 [16572121.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1300-3 [16673020.001]
  • [Cites] Nature. 2006 Nov 23;444(7118):444-54 [17122850.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):347-51 [17293865.001]
  • [Cites] J Exp Med. 2007 Mar 19;204(3):633-43 [17353367.001]
  • [Cites] Trends Biochem Sci. 2007 Nov;32(11):509-19 [17949986.001]
  • [Cites] Science. 2008 Mar 21;319(5870):1676-9 [18323416.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3701-13 [18160665.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1299-305 [15944719.001]
  • (PMID = 18765795.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; United States / NCI NIH HHS / CA / UO1-CA 114778; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2533222
  •  go-up   go-down


57. Martorell M, Gaona Morales JJ, Garcia JA, Manuel Gutierrez Herrera J, Grau FG, Calabuig C, Vallés AP: Transformation of vulvar pseudolymphoma (lymphoma-like lesion) into a marginal zone B-cell lymphoma of labium majus. J Obstet Gynaecol Res; 2008 Aug;34(4 Pt 2):699-705
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of vulvar pseudolymphoma (lymphoma-like lesion) into a marginal zone B-cell lymphoma of labium majus.
  • Diffuse large B-cell lymphoma and follicular lymphoma are the most common types.
  • We describe the case of an 80-year-old woman with a recurrent lesion in the vulva initially diagnosed as a lymphoma-like lesion and evolving 7 years later into a marginal zone B-cell lymphoma (lymphoplasmacytic lymphoma).
  • No previous cases of vulvar marginal zone B-cell lymphoma arising in the context of a persistent lymphoma-like lesion have been reported.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Pseudolymphoma / pathology. Vulva / pathology. Vulvar Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18840185.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


58. Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, Elstrom R, Lachs M, Hajjar KA, Leonard JP: Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer; 2010 Jun 1;116(11):2655-64
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.
  • BACKGROUND: Targeting the tumor microenvironment and angiogenesis is a novel lymphoma therapeutic strategy.
  • The authors report safety, activity, and angiogenic profiling results with the rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide (RT-PEPC) regimen in patients with recurrent mantle cell lymphoma (MCL).
  • The median age was 68 years (range, 52-81 years), 24 patients (96%) had stage III or IV disease, 18 patients (72%) had an International Prognostic Index (IPI) score of 3 to 5, and 20 patients (80%) had high-risk Mantle Cell International Prognostic Index (MIPI) scores.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Leuk Lymphoma. 2009 May;50(5):728-35 [19373598.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4342-6 [12907602.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):314-22 [15057291.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2269-71 [15166030.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1075-82 [7849295.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1984-92 [15668467.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2677-84 [15591112.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5347-56 [15983389.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7013-23 [16145068.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1608-16 [16249383.001]
  • [Cites] Blood. 2006 Jul 15;108(2):452-9 [16543470.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5190-8 [16951238.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1785-7 [16990548.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4003-8 [16946304.001]
  • [Cites] Leuk Lymphoma. 2008 Mar;49(3):447-50 [18297520.001]
  • [Cites] Cancer. 2008 May 15;112(10):2228-32 [18338745.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4952-7 [18606983.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):511-8 [19075279.001]
  • [Cites] Br J Haematol. 2009 May;145(3):344-9 [19245430.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1288-94 [11870171.001]
  • (PMID = 20235190.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL046403; United States / NHLBI NIH HHS / HL / K08 HL091517; United States / NHLBI NIH HHS / HL / R01 HL042493-18; United States / NHLBI NIH HHS / HL / R01 HL090895-03; United States / NHLBI NIH HHS / HL / R01 HL090895; United States / NHLBI NIH HHS / HL / HL042493-18; United States / NHLBI NIH HHS / HL / K08HL091517; United States / NHLBI NIH HHS / HL / R01 HL042493; United States / NHLBI NIH HHS / HL / P01 HL046403-19
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 35S93Y190K / Procarbazine; 4F4X42SYQ6 / Rituximab; 4Z8R6ORS6L / Thalidomide; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ NIHMS257257; NLM/ PMC3004744
  •  go-up   go-down


59. Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, Melnick A, Coleman M, Leonard JP: Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk; 2010 Jun;10(3):192-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.
  • BACKGROUND: Patients with diffuse large B-cell lymphoma (DLBCL) who are not cured by initial therapy sometimes experience disease-free survival after autologous stem cell transplantation.
  • CONCLUSION: Our data demonstrate that patients with recurrent DLBCL not responding to second-line chemotherapy demonstrate dismal outcomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / surgery. Neoplasm Recurrence, Local / surgery. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Stem Cell Transplantation. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20511164.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Duvic M, Vu J: Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc); 2007 Sep;43(9):585-99
Hazardous Substances Data Bank. Vorinostat .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vorinostat in cutaneous T-cell lymphoma.
  • HDAC-Is are able to induce differentiation, apoptosis and/or cell cycle arrest of malignant cells selectively.
  • Food and Drug Administration for treatment of the cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
  • In two phase II trials, Vorinostat was safe and effective at an oral dose of 400 mg/day with an overall response rate of 30-31% in refractory advanced patients with CTCL including large cell transformation and Sezary syndrome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Histone Deacetylase Inhibitors. Hydroxamic Acids / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Prous Science.
  • (PMID = 17940636.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  • [Number-of-references] 66
  •  go-up   go-down


61. Nagel S, Leich E, Quentmeier H, Meyer C, Kaufmann M, Zaborski M, Rosenwald A, Drexler HG, Macleod RA: Amplification at 11q23 targets protein kinase SIK2 in diffuse large B-cell lymphoma. Leuk Lymphoma; 2010 May;51(5):881-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification at 11q23 targets protein kinase SIK2 in diffuse large B-cell lymphoma.
  • In diffuse large B-cell lymphoma (DLBCL), several recurrent chromosomal aberrations have been described where the presumed target genes remain unknown, including gain/amplification at 11q23-24.
  • Here, we characterized amplification at 11q23 in the DLBCL cell line KARPAS-422.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Gene Amplification. Lymphoma, Large B-Cell, Diffuse / genetics. Protein-Serine-Threonine Kinases / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 May;51(5):743-4 [20233055.001]
  • (PMID = 20367563.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / SIK1 protein, human
  •  go-up   go-down


62. Shimoni A, Nagler A: Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma. Leuk Lymphoma; 2007 Nov;48(11):2110-20
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma.
  • High-dose chemotherapy and autologous stem-cell transplantation (ASCT) have an established therapeutic role in the treatment of chemo-sensitive relapsed aggressive lymphoma, but has limited success in chemo-refractory disease or in heavily pretreated, multiple relapsed patients.
  • Recurrent disease is the major cause of treatment failure in all patient subsets and the majority is not cured.
  • Methods for better eradication of underlying lymphoma are needed to improve outcome.
  • Two radioimmunoconjugates are currently approved for relapsed/resistant low-grade or transformed lymphoma: iodine-131 tositumomab and yttrium-90 ibritumomab tiuxetan.
  • These agents are also effective in aggressive lymphoma.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, B-Cell / therapy. Radioimmunotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891639.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 59
  •  go-up   go-down


63. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH: Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood; 2009 Jun 11;113(24):6069-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
  • Gene expression profiling of diffuse large B-cell lymphoma (DLBCL) has revealed distinct molecular subtypes that include germinal center B cell-like (GCB) and activated B cell-like (ABC) DLBCL.
  • As the proteasome inhibitor bortezomib can inhibit NF-kappaB through blocking IkappaBalpha degradation, we investigated bortezomib alone followed by bortezomib and doxorubicin-based chemotherapy in recurrent DLBCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Recurrence, Local / drug therapy


64. Fassiadis N, Ananos D, Zayed H, Rashid H: Lymphoma masquerading as a recurrent brachial artery aneurysm. Surgeon; 2008 Jun;6(3):182-3
MedlinePlus Health Information. consumer health - Aneurysms.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma masquerading as a recurrent brachial artery aneurysm.
  • Malignant lymphoma infiltrating the brachial artery in a renal transplant patient has not been documented previously.
  • We report an angiodestructive B-cell lymphoma in a 64-year-old post-renal transplant recipient.
  • [MeSH-major] Aneurysm / diagnosis. Brachial Artery. Lymphoma, B-Cell / diagnosis. Vascular Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581756.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


65. Al Hawashim N, Al Akwaa A: Coexistence of malakoplakia and multifocal diffuse large B cell lymphoma of colorectum. Colorectal Dis; 2009 Jan;11(1):99-100
Genetic Alliance. consumer health - Malakoplakia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of malakoplakia and multifocal diffuse large B cell lymphoma of colorectum.
  • We report a case of concurrent multifocal diffuse large B cell lymphoma and malakoplakia of colorectum in a 36-year-old man presenting with recurrent bloody diarrhoea.
  • To the best of our knowledge, this is the third report of coexistence or association of malignant non-Hodgkin lymphoma and malakoplakia in the literature, and the first report ever in the colorectum.
  • [MeSH-major] Colonic Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Malacoplakia / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462225.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


66. Haas RL, Poortmans P, de Jong D, Verheij M, van der Hulst M, de Boer JP, Bartelink H: Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. Eur J Cancer; 2005 Aug;41(12):1724-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients.
  • In this work, we have studied the response rates and duration of response after low-dose (4 Gy) involved field radiotherapy (LD-IF-RT) in relapsed or chemotherapy refractory indolent and aggressive lymphoma patients.
  • Patients included were those with small lymphocytic lymphoma/chronic lymphocytic leukaemia (n=23), marginal zone lymphoma, nodal type (n=18), mantle cell lymphoma (n=17), and diffuse large B-cell lymphoma (n=13).
  • None of the factors studied (age, sex, lymphoma subtype, radiotherapy regimen, number of prior regimens or time since diagnosis, number of positive sites or largest lymphoma diameter) were found to relate to response.
  • It appears that LD-IF-RT is a valuable asset in the management of relapsed disease in both indolent and aggressive lymphoma and should be considered to palliate symptoms in patients with recurrent and/or chemotherapy refractory disease.
  • [MeSH-major] Lymphoma / radiotherapy. Palliative Care / methods

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039113.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Salaverria I, Espinet B, Carrió A, Costa D, Astier L, Slotta-Huspenina J, Quintanilla-Martinez L, Fend F, Solé F, Colomer D, Serrano S, Miró R, Beà S, Campo E: Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. Genes Chromosomes Cancer; 2008 Dec;47(12):1086-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques.
  • Mantle cell lymphoma (MCL) is genetically characterized by 11q13 translocations leading to the overexpression of CCND1, and additional secondary genomic alterations that may be important in the progression of this disease.
  • We have analyzed 22 MCL cases and 10 MCL cell lines using multicolor fluorescence in situ hybridization (M-FISH), FISH, and comparative genomic hybridization (CGH).
  • All but one MCL cell line showed t(11;14) and structural and numerical alterations in highly complex karyotypes.
  • Besides 11 and 14, the most commonly rearranged chromosomes were 1, 8, and 10 in the tumors and 1, 8, and 9 in the cell lines.
  • No recurrent translocations other than the t(11;14) were identified.
  • However, we identified 17 recurrent breakpoints, the most frequent being 1p22 and 8p11, each observed in four cases and two cell lines.
  • Interestingly, five tumors and four cell lines displayed a complex t(11;14), cryptic in one case and two cell lines, preferentially involving chromosome 8.
  • In conclusion, MCL does not have recurrent translocations other than t(11;14), but shows recurrent chromosomal breakpoints.
  • [MeSH-major] Chromosome Breakage. Lymphoma, Mantle-Cell / genetics

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18709664.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Fung HC, Stiff P, Schriber J, Toor A, Smith E, Rodriguez T, Krishnan A, Molina A, Smith D, Ivers B, Kogut N, Popplewell L, Rodriguez R, Somlo G, Forman SJ, Nademanee A: Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant; 2007 May;13(5):594-600
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.
  • Although autologous stem cell transplantation (ASCT) for patients with relapsed/refractory Hodgkin lymphoma (HL) appears to offer a survival advantage over conventional therapy, only approximately 25% to 35% of patients with primary progressive or poor-risk recurrent HL can achieve durable remission after ASCT, with disease progressive after transplant accounting for most of the treatment failures.
  • ELIGIBILITY CRITERIA: primary progressive (n = 28) or recurrent HL (n = 18) with at least 1 of the following poor prognostic factors: first complete remission (CR) <12 months (n = 15) or extra-nodal disease (n = 4) or B symptoms at relapse (n = 4).
  • Of the 46 patients, 5 (11%) did not receive the planned tandem transplants because of inadequate stem cell collection for 2 ASCT.
  • Our mature results from this study suggest that in patients with primary progressive or poor risk recurrent HL, this tandem ASCT program is effective and well tolerated and compares favorably with the conventional single transplant.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasm Recurrence, Local / therapy. Peripheral Blood Stem Cell Transplantation / methods. Transplantation Conditioning / methods. Whole-Body Irradiation / methods

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448919.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Win N, Madan B, Gale R, Matthey F: Intravenous immunoglobulin given to lymphoma patients with recurrent haemolytic transfusion reactions after transfusion of compatible blood. Hematology; 2005 Oct;10(5):375-8
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous immunoglobulin given to lymphoma patients with recurrent haemolytic transfusion reactions after transfusion of compatible blood.
  • Accelerated destruction of red cells after transfusion of compatible blood has been reported in both sickle cell disease (SCD) and non-SCD patients.
  • We report three patients with lymphoma, all of whom had recurrent haemolytic transfusion reactions after receiving compatible red cell units.
  • The direct antiglobulin test (DAT) was negative and there were no detectable red cell alloantibodies in either pre-transfusion or post-transfusion samples.
  • As there was no evidence of red cell antibody-mediated haemolysis and response to oral steroids, a trial of intravenous immunoglobulin (IVIg) was given.
  • The response to IVIg in these cases suggests that IVIg should be tried when recurrent non-antibody mediated haemolytic transfusion reactions occur in patients with a lymphoid malignancy.
  • [MeSH-major] Blood Transfusion. Hemolysis / drug effects. Immunoglobulins, Intravenous / administration & dosage. Lymphoma / therapy. Steroids / administration & dosage

  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273724.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous; 0 / Steroids
  •  go-up   go-down


70. Coutinho AB, Muccioli C, Martins MC, Belfort Jr R, Sant'Anna AE, Burnier Jr MN: Extranodal B-cell lymphoma of the uvea: a case report. Can J Ophthalmol; 2005 Oct;40(5):623-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal B-cell lymphoma of the uvea: a case report.
  • CASE REPORT: Ocular involvement by non-Hodgkin's lymphoma is a rare condition that can result from a primary intraocular lymphoma of the retina or an intraocular manifestation of systemic lymphoma.
  • Uveal involvement is seldom the initial manifestation of extranodal lymphoma.
  • We describe an 80-year-old patient with a blind and painful left eye and a history of recurrent uveitis.
  • After ultrasound evaluation, the eye was enucleated and histopathologic examination revealed a malignant B-cell lymphoma of the uveal tract.
  • The patient has been followed for 8 years after surgery, but she has had no further systemic manifestations of lymphoma and has not required subsequent treatment.
  • COMMENTS: Primary extranodal lymphoma can be easily mistaken for recurrent uveitis or primary intraocular lymphoma of the retina and central nervous system; it is a differential diagnosis to be considered in cases of recurrent uveitis-like symptoms evolving to blind painful eye.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391629.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Mori T, Takimoto T, Katano N, Kikuchi A, Tabuchi K, Kobayashi R, Ayukawa H, Kumagai MA, Horibe K, Tsurusawa M: Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol; 2006 Mar;132(5):594-7
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan.
  • This report presents a retrospective study of 26 Japanese children with recurrent anaplastic large cell lymphoma.
  • The patients who received allogeneic haematopoietic stem cell transplantation during second CR showed a superior outcome to other patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large-Cell, Anaplastic / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease Progression. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Infant. Japan. Male. Neoplasm Recurrence, Local / mortality. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445832.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


72. Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS, Hayashi RJ, Termuhlen AM, Zhang MJ, Davies SM, Eapen M: Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant; 2010 Feb;16(2):223-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents.
  • We examined the role of hematopoietic stem cell transplantation (HSCT) for patients aged< or =18 years with refractory or recurrent Burkitt (n=41), lymphoblastic (n=53), diffuse large B cell (DLBCL; n=52), and anaplastic large cell lymphoma (n=36), receiving autologous (n=90) or allogeneic (n=92; 43 matched sibling and 49 unrelated donor) HSCT in 1990-2005.
  • Allogeneic donor HSCT was more likely to use irradiation-containing conditioning regimens, bone marrow (BM) stem cells, be performed in more recent years, and for lymphoblastic lymphoma.
  • After adjusting for disease status, 5-year EFS were similar after allogeneic and autologous HSCT for DLBCL (50% vs 52%), Burkitt (31% vs 27%), and anaplastic large cell lymphoma (46% vs 35%).
  • However, EFS was higher for lymphoblastic lymphoma, after allogeneic HSCT (40% vs 4%; P < .01).
  • Predictors of EFS for progressive or recurrent disease after HSCT included disease status at HSCT and use of allogeneic donor for lymphoblastic lymphoma.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Hematol Oncol Clin North Am. 1999 Oct;13(5):1091-112, viii-ix [10553263.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):897-903 [19139435.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):965-8 [11298592.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2390-6 [11331317.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]
  • [Cites] Cytotherapy. 2002;4(3):253-8 [12194721.001]
  • [Cites] Am J Hematol. 2003 Jan;72(1):53-63 [12508269.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):660-70 [12588354.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] Blood. 1992 Dec 1;80(11):2938-42 [1450419.001]
  • [Cites] Blood. 1993 Apr 15;81(8):2003-6 [8471762.001]
  • [Cites] Bone Marrow Transplant. 1995 Mar;15(3):353-9 [7599558.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2921-30 [9376572.001]
  • [Cites] Stat Med. 1999 Jun 30;18(12):1489-500 [10398287.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):70-6 [15368550.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):541-7 [15659500.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] Br J Haematol. 2006 Apr;133(2):176-82 [16611309.001]
  • [Cites] Ann Hematol. 2006 Nov;85(11):787-94 [16932891.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):840-7 [18371107.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):188-92 [18428432.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • (PMID = 19800015.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518-14; United States / NHLBI NIH HHS / HL / 5U01HL069294; United States / NCI NIH HHS / CA / U24 CA076518; United States / PHS HHS / / HHSH234200637015C; United States / NCI NIH HHS / CA / U24-CA76518; United States / NCI NIH HHS / CA / CA076518-14; United States / NHLBI NIH HHS / HL / U01 HL069294
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS217814; NLM/ PMC2911354
  •  go-up   go-down


73. Weniger MA, Barth TF, Möller P: Genomic alterations in Hodgkin's lymphoma. Int J Hematol; 2006 Jun;83(5):379-84
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic alterations in Hodgkin's lymphoma.
  • Cytogenetic analysis of Hodgkin's lymphoma (HL) is hampered by the scarcity of neoplastic cells within a sea of reactive cells.
  • Two recurrent chromosomal aberrations, namely gains of 2p13-p16 and 9p24, have been found by comparative genomic hybridization analysis in microdissected cells from cHL patients as well as in cHL cell lines, but not in NLPHL cells.
  • The available cHL cell lines are remarkably heterogeneous in their karyotypes, suggesting profound genomic instability leading to numeric chromosomal aberration and multiple chromosomal breaks and translocations.
  • In this article, we review genomic aberrations that may contribute to the development and maintenance of the morphologic and clinical presentation of these beta-cell lymphoma entities.
  • [MeSH-major] Chromosome Aberrations. Epigenesis, Genetic. Gene Expression Regulation, Leukemic. Genomic Instability. Hodgkin Disease / genetics
  • [MeSH-minor] Chromosomes, Human, Pair 2 / genetics. Chromosomes, Human, Pair 9 / genetics. Humans. Lymphoma, B-Cell / genetics. Nucleic Acid Hybridization / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11 [16341240.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] J Clin Pathol. 2002 Mar;55(3):162-76 [11896065.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Oct;38(2):126-36 [12939740.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):211-5 [15551733.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):549-52 [10676635.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1326-31 [14961078.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1404-13 [16206268.001]
  • [Cites] Nat Immunol. 2004 Sep;5(9):875-6 [15334080.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):352-6 [16049307.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3326-34 [15284123.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1474-7 [11830502.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Aug;31(4):316-25 [11433522.001]
  • [Cites] Cancer Cell. 2002 Jul;2(1):9-15 [12150820.001]
  • [Cites] Blood. 2001 Jan 15;97(2):496-501 [11154228.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2351-7 [14645011.001]
  • [Cites] Blood. 2000 Aug 1;96(3):808-22 [10910891.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):25-32 [15613285.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):678-82 [11340571.001]
  • [Cites] Blood Rev. 2006 Jan;20(1):1-13 [16426940.001]
  • [Cites] Blood. 2004 Jun 15;103(12 ):4630-5 [14976049.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):363-71 [10830743.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):593-606 [16077907.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):909-16 [15645496.001]
  • [Cites] Blood. 2003 Jan 15;101(2):706-10 [12393409.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 May;6(5):376-85 [15852042.001]
  • [Cites] Blood. 2002 Jan 15;99(2):618-26 [11781246.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):1007-13 [12213729.001]
  • [Cites] Oncogene. 2005 Dec 15;24(56):8259-67 [16091734.001]
  • [Cites] Blood. 2005 May 15;105(10):4051-9 [15677564.001]
  • [Cites] Cell Immunol. 2001 Jul 10;211(1):37-42 [11585386.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R93-R100 [15809278.001]
  • [Cites] J Med Genet. 2005 Jul;42(7):595-601 [15994882.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):393-401 [11241792.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4553-60 [15728122.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2214-9 [14523479.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1845-53 [11238128.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2679-84 [16532038.001]
  • [Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]
  • [Cites] Blood. 1999 Dec 15;94(12):3997-4010 [10590043.001]
  • [Cites] Int J Hematol. 2001 Aug;74(2):178-85 [11594519.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1220-35 [12393483.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1411-21 [16224207.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5002-7 [15047891.001]
  • [Cites] Adv Cancer Res. 2002;84:277-312 [11883530.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Dec;23(4):323-7 [9824205.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2493-500 [16304050.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3509-12 [15867338.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1824-30 [16094416.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5580-94 [11607811.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):45-52 [16007868.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1381-7 [11830490.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:52-6 [12078904.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):33-42 [15613286.001]
  • [Cites] Cell Biol Int. 2005 May;29(5):375-83 [15996491.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):196-203 [15644776.001]
  • [Cites] Br J Haematol. 2001 Mar;112(3):768-75 [11260082.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3974-85 [9731511.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1771-9 [8781434.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):251-62 [15803153.001]
  • [Cites] Curr Opin Oncol. 2004 Jan;16(1):25-31 [14685089.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6379-86 [16155023.001]
  • [Cites] Hematology. 2005 Apr;10(2):115-29 [16019457.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1571-8 [8608249.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2207-13 [14523473.001]
  • [Cites] Nat Immunol. 2005 Oct;6(10):1054-60 [16142238.001]
  • [Cites] Nat Immunol. 2003 Jun;4(6):525-32 [12717432.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):29-35 [12507887.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2606-9 [12750286.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3413-20 [11719382.001]
  • [Cites] Leukemia. 2004 Feb;18(2):356-8 [14614518.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):207-12 [10637266.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):540-50 [15229479.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):489-95 [12478664.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2565-74 [16331255.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1941-4 [16287070.001]
  • [Cites] Haematologica. 1999 Apr;84(4):298-305 [10190942.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):205-10 [11774265.001]
  • [Cites] Cell Signal. 2006 Apr;18(4):449-55 [15967637.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):873-81 [14982841.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2866-74 [9531597.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:19-22 [12078897.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):439-47 [15695385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Nat Rev Immunol. 2003 Nov;3(11):900-11 [14668806.001]
  • [Cites] Leukemia. 2002 May;16(5):937-9 [11986957.001]
  • [Cites] Histol Histopathol. 2004 Apr;19(2):637-50 [15024721.001]
  • [Cites] Histopathology. 2001 Apr;38(4):368-75 [11318902.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2535-42 [15572583.001]
  • [Cites] Blood. 2003 May 1;101(9):3681-6 [12511414.001]
  • (PMID = 16787866.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 94
  •  go-up   go-down


74. Martín-Subero JI, Klapper W, Sotnikova A, Callet-Bauchu E, Harder L, Bastard C, Schmitz R, Grohmann S, Höppner J, Riemke J, Barth TF, Berger F, Bernd HW, Claviez A, Gesk S, Frank GA, Kaplanskaya IB, Möller P, Parwaresch RM, Rüdiger T, Stein H, Küppers R, Hansmann ML, Siebert R, Deutsche Krebshilfe Network Project Molecular Mechanisms in Malignant Lymphomas: Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Cancer Res; 2006 Nov 1;66(21):10332-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma.
  • Chromosomal breakpoints affecting immunoglobulin (IG) loci are recurrent in many subtypes of B-cell lymphomas.
  • However, despite the predominant B-cell origin of the Hodgkin and Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL), the presence of chromosomal translocations in IG loci has not yet been systematically explored.
  • Our results show that chromosomal breakpoints affecting the IG loci are recurrent in cHL.
  • [MeSH-major] Chromosome Breakage. Genes, Immunoglobulin Heavy Chain. Hodgkin Disease / genetics. Reed-Sternberg Cells / metabolism

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17079453.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Immunoglobulin Constant Regions; 0 / Neoplasm Proteins; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
  •  go-up   go-down


75. Shiozawa E, Saito B, Yamochi-Onizuka T, Makino R, Takimoto M, Nakamaki T, Tomoyasu S, Ota H: Senile EBV-associated B-cell lymphoproliferative disorder of indolent clinical phenotype with recurrence as aggressive lymphoma. Pathol Int; 2007 Oct;57(10):688-93
Genetic Alliance. consumer health - Indolent B cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Senile EBV-associated B-cell lymphoproliferative disorder of indolent clinical phenotype with recurrence as aggressive lymphoma.
  • Senile EBV-associated B-cell lymphoproliferative disorder (LPD) was proposed as a new disease entity in 2003.
  • This condition has a high incidence in elderly people without underlying immunodeficiencies, and is characterized by EBV-positive B-cell proliferation with a polymorphic composition.
  • The polymorphic LPD (PLPD) subtype has a preferable prognosis, whereas the large cell lymphoma (LCL) subtype involves aggressive disease progression.
  • Reported herein is a case of senile EBV-BLPD with indolent clinical features and PLPD subtype in the initial phase that recurred as an aggressive lymphoma 3 years after the initial diagnosis.
  • In the recurrent phase, Southern blotting confirmed monoclonal proliferation of large lymphoid B-cells.
  • In both the initial and recurrent phases, polymerase chain reaction (PCR) yielded a single discrete band of a similar size due to an immunoglobulin heavy-chain gene rearrangement, indicating that the large lymphoid B-cells retained identical monoclonality throughout the histological progression and over the whole clinical course.
  • [MeSH-major] B-Lymphocytes / pathology. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / isolation & purification. Lymphoma, B-Cell / virology. Lymphoproliferative Disorders / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17803658.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / Immunoglobulin Heavy Chains; 0 / RNA, Viral
  •  go-up   go-down


76. Ohta H, Kusuki S, Yoshida H, Sato E, Hashii Y, Ozono K: Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning for a child with recurrent anaplastic large cell lymphoma. Int J Hematol; 2010 Jul;92(1):190-3
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning for a child with recurrent anaplastic large cell lymphoma.
  • Anaplastic large cell lymphoma (ALCL) is chemosensitive, but recurrence is frequently observed.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) has recently been reported to be effective against recurrent disease, suggesting a graft-versus-lymphoma effect.
  • We present a 3-year-old child with recurrent ALCL who underwent HSCT from an HLA-1-locus mismatched cord blood unit following reduced intensity conditioning with fludarabine, melphalan, and low-dose thoraco-abdominal irradiation.
  • He is well and free of disease 25 months after HSCT, which implies that reduced intensity conditioning may allow a sufficient graft-versus-lymphoma effect against ALCL while lessening treatment-related toxicities.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Large-Cell, Anaplastic / therapy. Transplantation Conditioning / methods


77. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L: Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer; 2007 Jun 15;109(12):2481-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.
  • BACKGROUND: The objective was to determine the prognostic value of functional imaging (FI) in predicting outcome of patients with recurrent/refractory Hodgkin lymphoma (HL) before undergoing high-dose chemotherapy with autologous stem cell transplantation (ASCT).
  • CONCLUSIONS: Pretransplant FI status predicts outcome in patients with recurrent/refractory HL.
  • [MeSH-major] Fluorodeoxyglucose F18. Gallium Radioisotopes. Hodgkin Disease / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 American Cancer Society.
  • (PMID = 17497648.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


78. Jellicoe P, Hopyan S: Can chronic recurrent multifocal osteomyelitis predispose to lymphoma of bone? A case report. J Pediatr Orthop B; 2008 Nov;17(6):329-32
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can chronic recurrent multifocal osteomyelitis predispose to lymphoma of bone? A case report.
  • Chronic recurrent multifocal osteomyelitis (CRMO) and B-cell lymphoma are fairly uncommon conditions that are seen in children.
  • We describe an unusual situation in which a site adjacent to a biopsy-documented site of CRMO presented 3.5 years later with B-cell lymphoma.
  • B-cell lymphoma can behave in an indolent manner and reports suggest that this condition can initially be mistaken for CRMO.
  • [MeSH-major] Bone Neoplasms / etiology. Lymphoma, B-Cell / etiology. Osteomyelitis / complications
  • [MeSH-minor] Adolescent. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antineoplastic Agents / therapeutic use. Chronic Disease. Humans. Knee Joint / pathology. Knee Joint / radiography. Male. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Recurrent Multifocal Osteomyelitis.
  • Genetic Alliance. consumer health - Osteomyelitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841069.001).
  • [ISSN] 1473-5865
  • [Journal-full-title] Journal of pediatric orthopedics. Part B
  • [ISO-abbreviation] J Pediatr Orthop B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents
  •  go-up   go-down


79. Feldman AL, Law M, Remstein ED, Macon WR, Erickson LA, Grogg KL, Kurtin PJ, Dogan A: Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia; 2009 Mar;23(3):574-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.
  • Oncogenes involved in recurrent chromosomal translocations serve as diagnostic markers and therapeutic targets in hematopoietic tumors.
  • In contrast to myeloid and B-cell neoplasms, translocations in peripheral T-cell lymphomas (PTCLs) are poorly understood.
  • Here, we identified recurrent translocations involving the multiple myeloma oncogene-1/interferon regulatory factor-4 (IRF4) locus in PTCLs.
  • IRF4 translocations exist in myeloma and some B-cell lymphomas, but have not been reported earlier in PTCLs.
  • Two cases with t(6;14)(p25;q11.2) had translocations between IRF4 and the T-cell receptor-alpha (TCRA) locus.
  • In total, 8 of the remaining 10 cases were cutaneous anaplastic large-cell lymphomas (ALCLs) without TCRA rearrangements (57% of cutaneous ALCLs tested).
  • These findings identified IRF4 translocations as a novel recurrent genetic abnormality in PTCLs.
  • Detecting these translocations may be useful in lymphoma diagnosis.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Genet Med. 2006 Jan;8(1):16-23 [16418595.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3653-61 [10845893.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):219-28 [11266530.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):686-94 [11455001.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Aug;129(1):1-9 [11520558.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1967-72 [12057901.001]
  • [Cites] Leukemia. 2006 Feb;20(2):313-8 [16341044.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):124-32 [17387297.001]
  • [Cites] J Pathol. 2007 Sep;213(1):99-105 [17582237.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Nov;46(11):1011-8 [17696193.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4293-7 [17709797.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2332-43 [17625604.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):516-26 [18275429.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2516-20 [17975015.001]
  • [Cites] Hum Pathol. 2008 Apr;39(4):557-63 [18234282.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3867-71 [18235046.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Med Res Rev. 2008 May;28(3):372-412 [17694547.001]
  • [Cites] Br J Dermatol. 2008 Jun;158(6):1280-7 [18410414.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1268-72 [17989713.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1139-43 [18401419.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):178-85 [18628085.001]
  • [Cites] Histopathology. 2000 Feb;36(2):136-44 [10672058.001]
  • [Cites] Leukemia. 2000 Mar;14(3):449-56 [10720141.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):773-9 [12428799.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):176-85 [12696066.001]
  • [Cites] Histopathology. 2003 Nov;43(5):462-9 [14636272.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Leuk Res. 1985;9(9):1139-48 [3877852.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):226-30 [9326949.001]
  • [Cites] J Invest Dermatol. 1997 Nov;109(5):636-40 [9347791.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2076-84 [9490693.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jun;22(2):114-21 [9598798.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):228-36 [10029454.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2949-51 [10077617.001]
  • [Cites] Am J Clin Pathol. 1999 Sep;112(3):319-29 [10478136.001]
  • [Cites] Leukemia. 2005 Jan;19(1):77-82 [15510210.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3058-65 [15626743.001]
  • [Cites] Hum Pathol. 2005 May;36(5):494-504 [15948116.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):421-9 [16191511.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2247-53 [16193085.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:131-5 [10707795.001]
  • (PMID = 18987657.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / P50 CA097274-07; United States / NCI NIH HHS / CA / P50 CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / interferon regulatory factor-4
  • [Other-IDs] NLM/ NIHMS70248; NLM/ PMC2656414
  •  go-up   go-down


80. Rubio-Moscardo F, Blesa D, Mestre C, Siebert R, Balasas T, Benito A, Rosenwald A, Climent J, Martinez JI, Schilhabel M, Karran EL, Gesk S, Esteller M, deLeeuw R, Staudt LM, Fernandez-Luna JL, Pinkel D, Dyer MJ, Martinez-Climent JA: Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood; 2005 Nov 1;106(9):3214-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.
  • Deletions of chromosome 8p are a recurrent event in B-cell non-Hodgkin lymphoma (B-NHL), suggesting the presence of a tumor suppressor gene.
  • A minimal deleted region (MDR) of 600 kb was defined in chromosome 8p21.3, with one mantle cell lymphoma cell line (Z138) exhibiting monoallelic deletion of 650 kb.
  • Resistance to apoptosis of cell lines with 8p21.3 deletion was reversed by restoration of TRAIL-R1 or TRAIL-R2 expression by gene transfection.
  • Our data suggest that TRAIL-R1 and TRAIL-R2 act as dosage-dependent tumor suppressor genes whose monoallelic deletion can impair TRAIL-induced apoptosis in B-cell lymphoma.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 8 / genetics. Genes, Tumor Suppressor / physiology. Lymphoma, B-Cell / genetics. Receptors, Tumor Necrosis Factor / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Apoptosis. Apoptosis Regulatory Proteins / metabolism. Cell Line, Tumor. Down-Regulation. Gene Expression Profiling. Humans. Membrane Glycoproteins / metabolism. Mutation / genetics. Receptors, TNF-Related Apoptosis-Inducing Ligand. TNF-Related Apoptosis-Inducing Ligand. Tumor Necrosis Factor-alpha / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051735.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Membrane Glycoproteins; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10A protein, human; 0 / TNFRSF10B protein, human; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


81. Sibon I, Yekhlef F, Vital A, Orgogozo JM: [Stroke-like presentation of cerebral lymphoma]. Rev Neurol (Paris); 2005 Jan;161(1):74-7
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stroke-like presentation of cerebral lymphoma].
  • [Transliterated title] Lymphome cérébral primitif à présentation pseudovasculaire.
  • INTRODUCTION: The clinical presentation of primary cerebral lymphoma can take on many forms.
  • CASE REPORT: We report the case of a patient who experienced recurrent neurological events mimicking stroke with normal brain MRI.
  • A biopsy was obtained and led to the diagnosis of primary B cell lymphoma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Stroke / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15678004.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


82. Doshi K, Stanciu J, Cervantes J, Rodrigues L, Gintautas J, Alwani A: Splenic non-Hodgkin's lymphoma presenting as recurrent kidney stones -- an "incidentaloma"? Proc West Pharmacol Soc; 2008;51:55-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic non-Hodgkin's lymphoma presenting as recurrent kidney stones -- an "incidentaloma"?
  • Splenic lymphoma, or primary malignant lymphoma of the spleen (PMLS), is an uncommon condition whose true nature is difficult to define due to the variable ways it has been classified.
  • Out of all non-Hodgkin's lymphomas it comprises less than 2% of cases.
  • Clinical features of splenic lymphoma are characterized by nonspecific systemic symptoms such as low grade fevers, night sweats and symptoms related to considerable splenomegaly.
  • Most of these lymphomas are of B-cell origin showing low or intermediate-grade lymphoma on histological analysis.
  • However, further investigation led to the discovery of splenic lymphoma, which was asymptomatic earlier but may have manifested symptoms that mimicked renal colic.
  • [MeSH-major] Kidney Calculi / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Splenic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544677.001).
  • [ISSN] 0083-8969
  • [Journal-full-title] Proceedings of the Western Pharmacology Society
  • [ISO-abbreviation] Proc. West. Pharmacol. Soc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Zhao MY, Auerbach A, D'Costa AM, Rapoport AP, Burger AM, Sausville EA, Stass SA, Jiang F, Sands AM, Aguilera N, Zhao XF: Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. Clin Cancer Res; 2009 Mar 1;15(5):1708-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
  • PURPOSE: This study aimed to identify and evaluate molecular targets for the development of a novel combination chemotherapy to treat refractory and recurrent diffuse large B-cell lymphoma (DLBCL).
  • EXPERIMENTAL DESIGN: Lymphoma samples from 38 cases of primary and recurrent DLBCL were analyzed using real-time quantitative PCR of the RPS6KB1 and CDC2 genes, and immunohistochemistry for their gene products p70S6K/p85S6K and cdc2/cdk1.
  • The Farage, Karpas422, Pfeiffer, and Toledo DLBCL cell lines were subsequently treated with rapamycin and UCN-01 alone or in combination.
  • Cell proliferation, apoptosis, and cell cycle progression were analyzed after the drug treatment.
  • In addition, the levels of several key protein kinases involved in the phosphoinositide 3'-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, apoptosis, and cell cycle progression were analyzed in the presence and absence of the drugs.
  • RESULTS: Amplification of the RPS6KB1 and CDC2 genes was found in both primary and recurrent DLBCL.
  • The combination of rapamycin and UCN-01 synergistically inhibited the DLBCL cell proliferation by inducing G1 arrest as well as apoptosis by suppressing the phosphorylation of p70S6K/p85S6K and CDC2 expression.
  • This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. CDC2 Protein Kinase / metabolism. Cyclin B / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Recurrence, Local / pathology. Ribosomal Protein S6 Kinases, 70-kDa / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / drug effects. Blotting, Western. Cell Proliferation / drug effects. Cyclin-Dependent Kinases. Drug Synergism. Female. Flow Cytometry. G1 Phase / drug effects. Gene Expression Profiling. Humans. Immunoenzyme Techniques. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Phosphatidylinositol 3-Kinases / genetics. Phosphatidylinositol 3-Kinases / metabolism. Phosphorylation / drug effects. Protein Kinases / genetics. Protein Kinases / metabolism. Proto-Oncogene Proteins c-akt / genetics. Proto-Oncogene Proteins c-akt / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sirolimus / administration & dosage. Staurosporine / administration & dosage. Staurosporine / analogs & derivatives. TOR Serine-Threonine Kinases. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223503.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDK1 protein, human; 0 / Cyclin B; 0 / RNA, Messenger; 7BU5H4V94A / 7-hydroxystaurosporine; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 2.7.11.1 / ribosomal protein S6 kinase, 70kD, polypeptide 1; EC 2.7.11.22 / CDC2 Protein Kinase; EC 2.7.11.22 / Cyclin-Dependent Kinases; H88EPA0A3N / Staurosporine; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


84. Sambade C, Berglund M, Lagercrantz S, Sällström J, Reis RM, Enblad G, Glimelius B, Sundström C: U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma. Int J Cancer; 2006 Feb 1;118(3):555-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma.
  • Several patterns of association between Hodgkin and non-Hodgkin lymphomas are recognized, some of which support a common cellular origin or shared transformation events for both malignancies.
  • We describe the U-2940 cell line derived from a diffuse large B-cell lymphoma with some features consistent with mediastinal large B-cell lymphoma, clinically apparent 1 month after the initial course of chemotherapy for Hodgkin's disease, fulfilling the criteria for composite malignancies.
  • The cell line is negative for Epstein-Barr virus and no evidence of t(14;18) was found.
  • U-2940 cells display multiple chromosomal rearrangements similar to recurrent aberrations described in both Hodgkin and non-Hodgkin lymphomas, also partially shared by U-2932 derived from a B-cell lymphoma sequential to Hodgkin's disease.
  • The original large B-cell lymphoma and the U-2940 cell line bear microsatellite instability, an abnormality associated with particular subtypes of non-Hodgkin lymphomas and found in tissues involved by Hodgkin lymphoma.
  • Therefore, U-2940 cells bear several features known to occur in Hodgkin and in non-Hodgkin lymphomas, leading to the assumption that this cell line may constitute a useful tool to address elective pathways of lymphomagenesis and eventually the Hodgkin and non-Hodgkin lymphoma association.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adolescent. Animals. Cell Line, Tumor. Chromosome Aberrations. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Colony-Forming Units Assay. DNA, Neoplasm / analysis. Epstein-Barr Virus Infections / etiology. Epstein-Barr Virus Infections / pathology. Female. Gene Rearrangement. Herpesvirus 4, Human / pathogenicity. Humans. Immunoglobulin Heavy Chains / genetics. Mice. Mice, Nude. Spectral Karyotyping. Translocation, Genetic


85. Wildes TM, Bartlett NL: Drug development for recurrent and refractory classical Hodgkin lymphoma. Leuk Lymphoma; 2009 Apr;50(4):529-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug development for recurrent and refractory classical Hodgkin lymphoma.
  • Classical Hodgkin lymphoma (cHL) is highly treatable with chemotherapy alone or combined modality therapy.
  • High dose therapy and autologous stem cell transplant is considered standard of care for patients who relapse.
  • Targeted therapies for relapsed Hodgkin lymphoma include monoclonal antibodies directed at cell surface antigens, immunoconjugates, bispecific constructs created to recruit host effector cells and radioimmunotherapy.
  • In Epstein-Barr virus (EBV)-associated Hodgkin lymphoma, cytotoxic T lymphocytes directed at EBV antigens have been utilised in clinical trials with some success.
  • Additionally, the immunomodulatory agents thalidomide and lenalidomide, and new classes of drugs such as the mammalian target of rapamycin inhibitors and histone deacetylase inhibitors hold promise in relapsed Hodgkin lymphoma.
  • [MeSH-major] Drug Therapy / methods. Hodgkin Disease / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19373650.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoconjugates; 0 / Immunotoxins
  • [Number-of-references] 84
  •  go-up   go-down


86. Gerlinger M, Rohatiner AZ, Matthews J, Davies A, Lister TA, Montoto S: Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management. Haematologica; 2010 Jul;95(7):1130-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management.
  • BACKGROUND: The impact of active surveillance, comprising annual computed tomography scanning and bone marrow biopsies, in the follow-up of patients after high-dose therapy with autologous stem cell rescue for recurrent follicular lymphoma was analyzed.
  • CONCLUSIONS: Surveillance investigations, consisting of annual computed tomography scanning and bone marrow biopsies, have no impact on the management of patients with recurrent follicular lymphoma and do not improve the outcome of these patients.
  • [MeSH-major] Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Examination. Disease Management. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Tomography. Transplantation, Autologous

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):527-36 [10653868.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):123-5 [12691151.001]
  • [Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6 [2456618.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii77-8 [18456778.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1110-7 [9060552.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):909-13 [16672295.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2426-33 [17485708.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2554-9 [17515573.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):140-7 [7799014.001]
  • (PMID = 20107155.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2895037
  •  go-up   go-down


87. Hernandez C, Puangsuvan SN, Peterson A, Robinson JK: Localized perineal cutaneous nodules: a case of recurrent systemic anaplastic large-cell lymphoma. Clin Exp Dermatol; 2009 Dec;34(8):e722-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized perineal cutaneous nodules: a case of recurrent systemic anaplastic large-cell lymphoma.
  • We report an unusual case of localized cutaneous nodules heralding the recurrence of systemic CD30+ anaplastic large-cell lymphoma (ALCL).
  • A 47-year-old woman developed numerous violaceous nodules in the perineal and upper thigh area 3 years after multimodal treatment and complete remission of primary anaplastic large-cell CD30+ lymphoma.
  • Using immunohistochemical and T-cell gene rearrangement analysis, a recurrence of her anaplastic large-cell lymphoma was diagnosed.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antigens, CD30 / genetics. Cell Transformation, Neoplastic / genetics. Female. Gene Rearrangement, T-Lymphocyte / genetics. Humans. Middle Aged. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055841.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


88. Higuchi M, Muta T, Karube KN, Eto T, Yamano Y, Ohshima K: Epstein-Barr virus-positive blastoid variant of mantle cell lymphoma in an adult with recurrent infectious mononucleosis-like symptoms: a case report. Int J Hematol; 2007 Apr;85(3):219-22
MedlinePlus Health Information. consumer health - Infectious Mononucleosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positive blastoid variant of mantle cell lymphoma in an adult with recurrent infectious mononucleosis-like symptoms: a case report.
  • Epstein-Barr virus (EBV) is closely associated with several lymphomas, such as Burkitt lymphoma, natural killer/T-cell lymphoma, peripheral T-cell lymphoma, and Hodgkin's lymphoma; however, whether EBV is implicated in mantle cell lymphoma (MCL) has not been established.
  • We report the case of an adult with recurrent infectious mononucleosis (IM)-like symptoms who developed an EBV-positive blastoid variant of MCL.
  • He had a history of recurrent IM-like symptoms (prolonged fever and cervical lymphadenopathy) for at least 1 year.
  • EBV was detected in most of the lymphoma cells and in the peripheral blood.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / pathogenicity. Infectious Mononucleosis / virology. Lymph Nodes / pathology. Lymphoma, Mantle-Cell / virology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 1999 Jan;37(1):132-6 [9854077.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):569-78 [11568749.001]
  • [Cites] Int J Hematol. 1998 Feb;67(2):165-74 [9631583.001]
  • [Cites] Blood. 2001 Jul 15;98(2):280-6 [11435294.001]
  • [Cites] J Pathol. 1995 Mar;175(3):263-71 [7745495.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2028-32 [12727814.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2067-78 [9058729.001]
  • [Cites] Intern Med. 2004 Oct;43(10):986-9 [15575253.001]
  • [Cites] J Virol. 1996 Dec;70(12):9003-7 [8971032.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1785-91 [11681422.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7013-23 [16145068.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4407-12 [14645431.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):317-24 [10637245.001]
  • [Cites] Nature. 1970 Dec 12;228(5276):1056-8 [4320657.001]
  • [Cites] Int J Hematol. 2003 Jul;78(1):24-31 [12894847.001]
  • [Cites] Int J Hematol. 2000 Apr;71(3):259-62 [10846832.001]
  • [Cites] Blood. 1991 Feb 15;77(4):799-808 [1847084.001]
  • [Cites] Intern Med. 2005 Oct;44(10):1097-9 [16293926.001]
  • [Cites] Am J Hematol. 2003 Jul;73(3):194-9 [12827658.001]
  • [Cites] N Engl J Med. 1989 Feb 23;320(8):502-6 [2536894.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3803-9 [9850025.001]
  • (PMID = 17483058.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Romeike BF, Joellenbeck B, Stein H, Loddenkemper C, Hummel M, Firsching R, Mawrin C: Precursor T-lymphoblastic lymphoma within a recurrent pituitary adenoma. Acta Neurochir (Wien); 2008 Aug;150(8):833-6
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor T-lymphoblastic lymphoma within a recurrent pituitary adenoma.
  • Only single examples of lymphoma associated with pituitary adenoma have been reported.
  • In our patient, a precursor T-lymphoblastic lymphoma developed within a recurrent pituitary adenoma 17 years after the first resection.
  • Histomorphologically, lymphoma and adenoma components were tightly admixed.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Pituitary Neoplasms / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574548.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


90. Nishikori M, Uchiyama T: Molecular pathogenesis of Hodgkin lymphoma. Int J Hematol; 2006 Jun;83(5):398-403
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of Hodgkin lymphoma.
  • Hodgkin lymphoma (HL) is a distinctive lymphoma subtype that accounts for approximately 30% of all lymphomas in the Western world and approximately 5% in Japan.
  • HL is characterized by the giant multinucleated tumor cells called Hodgkin/Reed-Sternberg (H/RS) cells, but the cellular origin had long been unknown.
  • Recent investigations have clarified that H/RS cells have a clonally rearranged immunoglobulin gene in most cases, but it still seems appropriate to differentiate HL from other B-cell neoplasms, because the transforming event rather than its cellular origin is more likely to influence the nature of H/RS cells.
  • Most HL patients are cured with current treatment strategies, but some of them have refractory or recurrent disease, and intensified treatment occasionally induces therapy-related secondary malignancies.
  • [MeSH-major] Hodgkin Disease / etiology. Hodgkin Disease / genetics
  • [MeSH-minor] B-Lymphocytes / pathology. Cell Differentiation / genetics. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Disease-Free Survival. Gene Rearrangement, B-Lymphocyte / genetics. Humans. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / etiology. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / genetics. Neoplasms, Second Primary / pathology. Recurrence. Reed-Sternberg Cells / pathology. Signal Transduction / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Apr 1;101(7):2789-96 [12456498.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2784-90 [11675352.001]
  • [Cites] Blood. 2002 May 1;99(9):3398-403 [11964309.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4166-78 [12907455.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1685-91 [10362793.001]
  • [Cites] Immunity. 2002 Dec;17 (6):781-93 [12479824.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3326-34 [15284123.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Blood. 2001 Jan 15;97(2):496-501 [11154228.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] Blood. 2004 Jan 1;103(1):188-93 [12881301.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):395-402 [10637284.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1452-8 [15973455.001]
  • [Cites] J Clin Invest. 2003 Feb;111(4):529-37 [12588891.001]
  • [Cites] Science. 2002 Jul 5;297(5578):110-3 [12098702.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2065-71 [10477736.001]
  • [Cites] Blood. 2000 May 15;95(10):3020-4 [10807764.001]
  • [Cites] Histopathology. 2005 Feb;46(2):217-28 [15693895.001]
  • [Cites] Cell. 1985 Dec;43(3 Pt 2):831-40 [3000618.001]
  • [Cites] Nat Immunol. 2006 Feb;7(2):207-15 [16369535.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):387-94 [10637283.001]
  • [Cites] EMBO J. 2002 Aug 1;21(15):4104-13 [12145210.001]
  • [Cites] Blood. 2005 May 15;105(10):4051-9 [15677564.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Blood. 1996 May 15;87(10):4340-7 [8639794.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5640-3 [11059754.001]
  • [Cites] J Clin Invest. 1978 Jun;61(6):1620-7 [149140.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11963-8 [9751773.001]
  • [Cites] Curr Opin Immunol. 2002 Apr;14(2):216-23 [11869895.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):605-17 [12208876.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2493-503 [11971184.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1755-62 [14604957.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3129-34 [10556199.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jun;83(12):4167-71 [2424019.001]
  • [Cites] Am J Pathol. 1990 Jun;136(6):1209-14 [2356855.001]
  • [Cites] Pathol Int. 2000 Sep;50(9):696-702 [11012982.001]
  • [Cites] Blood. 1997 May 15;89(10):3787-94 [9160685.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3063-70 [10340377.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):997-1006 [14982853.001]
  • [Cites] EMBO J. 1997 Oct 15;16(20):6131-40 [9359753.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5251-60 [15289331.001]
  • [Cites] J Pathol. 2003 Nov;201(3):413-20 [14595753.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):943-53 [10023670.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1443-50 [10666223.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):300-9 [12872349.001]
  • [Cites] J Virol. 2000 Feb;74(4):1727-35 [10644343.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2080-4 [11280769.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7628-34 [16140928.001]
  • (PMID = 16787869.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 52
  •  go-up   go-down


91. Scandurra M, Rossi D, Deambrogi C, Rancoita PM, Chigrinova E, Mian M, Cerri M, Rasi S, Sozzi E, Forconi F, Ponzoni M, Moreno SM, Piris MA, Inghirami G, Zucca E, Gattei V, Rinaldi A, Kwee I, Gaidano G, Bertoni F: Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. Hematol Oncol; 2010 Jun;28(2):62-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas.
  • Richter's syndrome (RS) represents the transformation of chronic lymphocytic leukaemia (CLL) to aggressive lymphoma and is mostly represented by diffuse large B-cell lymphoma (DLBCL), with a post-germinal centre (GC) phenotype, clonally related to the pre-existing CLL.
  • MYCN, a c-MYC homologue, was also recurrently gained.
  • By comparing RS with 48 de novo DLBCL, RS presented a significantly lower prevalence of deletions affecting the PRDM1 and TNFAIP3, genes on 6q, known to be associated with a post-GC phenotype.
  • In conclusion, the genomic profile of RS seems to differ from what observed in de novo DLBCL and in other transformed DLBCL.
  • [MeSH-major] Gene Expression Profiling. Lymphoma, Large B-Cell, Diffuse / genetics
  • [MeSH-minor] Chromosome Aberrations. Chromosomes, Human, Pair 6 / genetics. DNA-Binding Proteins. Disease Progression. Gene Rearrangement, B-Lymphocyte. Genes, myc. Genes, p53. Humans. Intracellular Signaling Peptides and Proteins / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. MicroRNAs / genetics. Nuclear Proteins / genetics. Phenotype. Recurrence. Repressor Proteins / genetics. Sequence Deletion. Syndrome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 20014148.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / MicroRNAs; 0 / Nuclear Proteins; 0 / Repressor Proteins; 138415-26-6 / PRDM1 protein, human; EC 6.3.2.19 / TNFAIP3 protein, human
  •  go-up   go-down


92. Ikonomou IM, Tierens A, Troen G, Aamot HV, Heim S, Lauritzsen GF, Vålerhaugen H, Delabie J: Peripheral T-cell lymphoma with involvement of the expanded mantle zone. Virchows Arch; 2006 Jul;449(1):78-87
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma with involvement of the expanded mantle zone.
  • Peripheral T-cell lymphoma (PTCL) with a nodular architecture is rare.
  • Recently, two variants have been described with infiltration of the B-cell follicle, one variant that localizes to the marginal zone with a so-called perifollicular growth pattern, and a variant that localizes to the germinal center.
  • We have studied five similar cases of PTCL with involvement of the B-cell follicle.
  • However, our cases differ from the cases previously described by their predominant and frequently patchy involvement of the expanded mantle zone of the B-cell follicle at onset.
  • Cytogenetics was available in four of the cases but revealed no recurrent chromosomal aberrations or changes associated with other types of PTCL.
  • Whether our cases are part of a spectrum of PTCLs that encompasses previously described variants with predominant marginal zone or germinal center infiltration or they represent a separate T-cell lymphoma type remains to be demonstrated by a study of more of such cases.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, Mantle-Cell / pathology. Lymphoma, T-Cell, Peripheral / pathology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2005 Mar;123(3):448-55 [15716242.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):117-22 [10632495.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):161-70 [9171827.001]
  • [Cites] Bone Marrow Transplant. 2002 May;29(9):799-801 [12040480.001]
  • [Cites] Nature. 1994 Dec 8;372(6506):556-9 [7990929.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13823-8 [9811885.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):1067-71 [10702422.001]
  • [Cites] Int J Hematol. 2001 Feb;73(2):262-5 [11372742.001]
  • [Cites] Eur J Immunol. 1998 May;28(5):1604-10 [9603466.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3369-73 [12384439.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Lab Invest. 2001 Dec;81(12):1693-702 [11742039.001]
  • [Cites] Eur J Immunol. 1999 Nov;29(11):3729-36 [10556829.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):46-55 [7856738.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):297-303 [7872427.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2640-8 [7919378.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Feb;117(1):71-9 [10700871.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):751-8 [8657279.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):395-400 [11224611.001]
  • [Cites] Blood. 1995 Jul 1;86(1):45-53 [7795255.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12520-4 [8618933.001]
  • [Cites] Blood. 2001 Jan 1;97(1):270-6 [11133771.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2445-50 [9310496.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):403-11 [10208461.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):643-55 [9630171.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11816-21 [9751748.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):133-8 [3257382.001]
  • (PMID = 16633785.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-bcl-6
  •  go-up   go-down


93. Kaufmann Y, Amariglio N, Rosenthal E, Hirsch YJ, Many A, Rechavi G: Proliferation response of leukemic cells to CD70 ligation oscillates with recurrent remission and relapse in a low-grade lymphoma. J Immunol; 2005 Nov 15;175(10):6940-7
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferation response of leukemic cells to CD70 ligation oscillates with recurrent remission and relapse in a low-grade lymphoma.
  • Interactions of the TNF-related cell surface ligand CD70 with its receptor CD27 provide a costimulatory signal in B and T cell activation.
  • Functional CD70-CD27 interactions could contribute to lymphoma and leukemia progression.
  • This possibility was studied using DNA microarrays on a unique case of low-grade lymphoma/leukemia characterized by recurrent cycles of acute leukemic phase alternating with spontaneous remission.
  • Hence, in this lymphoma/leukemia, membrane CD70 is presented on the leukemic cells in a responsive state during the remission and a nonresponsive state during the attack.
  • [MeSH-major] Antigens, CD / metabolism. Leukemia / immunology. Leukemia / pathology. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / pathology. Membrane Proteins / metabolism. Tumor Necrosis Factors / metabolism
  • [MeSH-minor] Antigens, CD27 / blood. Antigens, CD27 / genetics. Antigens, CD70. Apoptosis. Base Sequence. Cell Membrane / immunology. Cell Proliferation. DNA, Neoplasm / genetics. Gene Expression Profiling. Humans. Ligands. Recurrence

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16272354.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD27; 0 / Antigens, CD70; 0 / CD70 protein, human; 0 / DNA, Neoplasm; 0 / Ligands; 0 / Membrane Proteins; 0 / Tumor Necrosis Factors
  •  go-up   go-down


94. Matsuo T, Ichimura K, Yoshino T: Spontaneous regression of bilateral conjunctival extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. J Clin Exp Hematop; 2007 Nov;47(2):79-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of bilateral conjunctival extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
  • We report the case of a patient who showed spontaneous regression of bilateral conjunctival extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
  • Histopathology and immunohistochemistry showed MALT lymphoma with immunoglobulin kappa monotype shared by the lesions in both eyes.
  • Because the patient had recurrent pulmonary tuberculosis, radiation initially planned for the large residual lesion in the right eye was postponed.
  • The spontaneous regression of conjunctival MALT lymphoma observed in this patient suggests that following excisional biopsy for histopathological diagnosis, observation is a treatment option.
  • [MeSH-major] Conjunctival Neoplasms / pathology. Conjunctival Neoplasms / surgery. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18040147.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


95. Keller CE, Nandula S, Vakiani E, Alobeid B, Murty VV, Bhagat G: Intrachromosomal rearrangement of chromosome 3q27: an under recognized mechanism of BCL6 translocation in B-cell non-Hodgkin lymphoma. Hum Pathol; 2006 Aug;37(8):1093-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrachromosomal rearrangement of chromosome 3q27: an under recognized mechanism of BCL6 translocation in B-cell non-Hodgkin lymphoma.
  • Balanced reciprocal translocations involving chromosomal region 3q27, which led to identification of the BCL6 protooncogene, are one of the most common recurrent chromosomal abnormalities reported in B-cell non-Hodgkin lymphomas (B-NHL).
  • Cloning of the breakpoints of these translocations has facilitated the identification of a number of BCL6 partners including immunoglobulin genes and more than 20 non-immunoglobulin genes on almost all human chromosomes.
  • These rearrangements accounted for 3/20 (15%) of all BCL6 translocations occurring in B-NHL, including follicular lymphomas, diffuse large B-cell lymphomas, and marginal zone B-cell lymphomas, diagnosed at our institute.
  • [MeSH-major] Chromosomes, Human, Pair 3. DNA-Binding Proteins / genetics. Gene Rearrangement. Lymphoma, B-Cell / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867873.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins
  •  go-up   go-down


96. Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Cabanillas F, Tiongson LP, Younes A: Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Sep;47(9):1818-21
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
  • Although numerous options are available for patients with recurrent low-grade non-Hodgkin's lymphoma (NHL), responses are rarely durable.
  • We previously conducted a phase I trial of fludarabine and paclitaxel in the treatment of recurrent low-grade lymphoma.
  • The present phase II study was performed to determine the activity of fludarabine and paclitaxel in patients with recurrent low-grade NHL.
  • Patients with histologically confirmed recurrent low-grade NHL were treated with fludarabine 20 mg/m2/day intravenously (i.v.) on days 1-5 plus paclitaxel 50 mg/m2 given by i.v. continuous infusion over 72 h starting on day 1.
  • Twenty-two (78%) patients had grade 1 or 2 follicular lymphoma, and six patients (21%) had small lymphocytic lymphoma.
  • The combination of fludarabine and paclitaxel has clinical activity in patients with recurrent low-grade NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy. Male. Middle Aged. Paclitaxel / administration & dosage. Survival Rate. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064994.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


97. Bhattacharyya I, Chehal HK, Cohen DM, Al-Quran SZ: Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification. Head Neck Pathol; 2010 Sep;4(3):181-91
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.
  • Primary lymphomas of the oral cavity are rare and the most frequent type is diffuse large B-cell lymphoma (DLBCL).
  • Recently, several reports have highlighted the value of classifying DLBCL into prognostically important subgroups, namely germinal center B-cell like (GCB) and non-germinal center B-cell like (non-GCB) lymphomas based on gene expression profiles and by immunohistochemical expression of CD10, BCL6 and MUM-1.
  • GCB lymphomas tend to exhibit a better prognosis than non-GCB lymphomas.
  • IHC was performed using antibodies against germinal center markers (CD10, BCL6), activated B-cell markers (MUM1, BCL2) and Ki-67 (proliferation marker).
  • Cases were sub-classified as GCB subgroup if CD10 and/or BCL6 were positive and MUM-1, was negative and as non-GCB subgroup if CD10 was negative and MUM-1 was positive.
  • Therefore, 8/13 (58%) were sub-classified as non-GCB DLBCLs and 5/13 (42%) as GCB subgroup.
  • Four of the 8 patients with non-GCB subgroup succumbed to their disease, with the mean survival rate of 16 months.
  • Four of the 5 patients in the GCB subgroup were alive with no evidence of disease and one patient succumbed to complications of therapy and recurrent disease after 18 months.
  • In conclusion, our analysis shows that primary oral DLBCL predominantly belongs to the non-GCB subgroup, which tends to exhibit a poorer prognosis.
  • [MeSH-major] Germinal Center / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mouth Neoplasms / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1998 Aug;25(4):483-91 [9728598.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):117-22 [9894462.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):423-9 [10458261.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):545-51 [15517363.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):398-405 [15492762.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):303-10 [15716836.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):247-57 [16342164.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1521-7 [16998463.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):447-54 [18086797.001]
  • [Cites] Hematology. 2009 Apr;14(2):84-9 [19298719.001]
  • [Cites] Cancer Sci. 2009 Oct;100(10):1842-7 [19656156.001]
  • [Cites] Mod Pathol. 2010 Feb;23(2):235-43 [19935644.001]
  • [Cites] Blood. 2000 Jan 15;95(2):651-9 [10627476.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1797-803 [10688840.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):846-52 [10843287.001]
  • [Cites] Immunity. 2000 Aug;13(2):199-212 [10981963.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1244-52 [11106083.001]
  • [Cites] Mod Pathol. 2001 Feb;14(2):105-10 [11235901.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):325-34 [11555708.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):1089-98 [11697626.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):153-7 [11957138.001]
  • [Cites] Br J Haematol. 2002 May;117(2):322-32 [11972514.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] J Pathol. 1988 Mar;154(3):223-35 [2450981.001]
  • [Cites] J Clin Pathol. 1989 Nov;42(11):1194-200 [2531171.001]
  • [Cites] Am J Pathol. 1990 Aug;137(2):225-32 [2201196.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1190-7 [2205355.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):231-6 [8508412.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Science. 1993 Oct 29;262(5134):747-50 [8235596.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Mod Pathol. 2002 Aug;15(8):807-16 [12181265.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1366-73 [12481019.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):722-8 [12576441.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1063-9 [12631608.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1269-77 [12960812.001]
  • [Cites] Histopathology. 2003 Dec;43(6):509-28 [14636252.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3498-506 [15337798.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5948-55 [15342373.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):407-12 [3819806.001]
  • [Cites] Ann Intern Med. 1987 Jul;107(1):25-30 [3296898.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994;30B(2):121-5 [8032301.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Pathol. 1996 May;148(5):1543-55 [8623923.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Aug;82(2):173-8 [8863307.001]
  • (PMID = 20533006.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC2923304
  •  go-up   go-down


98. Gockel HR, Heidemann J, Lugering A, Mesters RM, Parwaresch R, Domschke W, Lugering N: Stable remission after administration of rituximab in a patient with primary hepatic marginal zone B-cell lymphoma. Eur J Haematol; 2005 May;74(5):445-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stable remission after administration of rituximab in a patient with primary hepatic marginal zone B-cell lymphoma.
  • We describe a case of primary hepatic marginal zone B-cell lymphoma in a 36-year-old Caucasian male with a history of chronic hepatitis B infection.
  • Immunohistochemically, extensive infiltration by a CD20-positive, CD5- negative and CD10-negative lymphoid cell population displaying a follicular arrangement was detected.
  • Molecular analysis of immunoglobulin heavy chain gene rearrangements confirmed the clonal expansion of lymphoma cells.
  • Six, 10, 18, and 26 months later the recurrent lymphoma could no longer be detected as shown by abdominal ultrasonography and CT.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Liver Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15813921.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


99. Biswas T, Dhakal S, Chen R, Hyrien O, Bernstein S, Friedberg JW, Fisher RI, Liesveld J, Phillips G, Constine LS: Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. Int J Radiat Oncol Biol Phys; 2010 May 1;77(1):79-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.
  • PURPOSE: For patients with recurrent or refractory large B-cell non-Hodgkin's lymphoma, high-dose chemotherapy and autologous stem cell transplant (ASCT) is the treatment of choice.
  • MATERIALS AND METHODS: Between May 1992 and April 2005, 176 patients underwent ASCT for recurrent or refractory large B-cell non-Hodgkin's lymphoma; 164 patients were evaluable for endpoint analysis.
  • CONCLUSIONS: Recognizing that positive and negative patient selection bias exists for the use of IFRT post-ASCT, patients initially treated with CHOP or R-CHOP and who undergo ASCT for recurrent or refractory disease may benefit from subsequent IFRT presumably due to enhanced local control that can translate into a survival advantage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / therapy. Stem Cell Transplantation / methods

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647953.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


100. Sorá F, Piccirillo N, Chiusolo P, Laurenti L, Marra R, Bartolozzi F, Leone G, Sica S: Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma. Cancer; 2006 Feb 15;106(4):859-66
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma.
  • BACKGROUND: The objective of the current study was to evaluate a salvage chemotherapy regimen consisting of mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone (MiCMA) for the treatment of patients with primary refractory or recurrent non-Hodgkin lymphoma (NHL).
  • METHODS: From September 1991 to August 2002, 94 consecutive patients ages 16-60 years who had either recurrent or refractory NHL (mainly diffuse large-cell lymphomas) were treated on the MiCMA protocol.
  • Patients had peripheral blood stem cells collected successfully for autologous stem cell transplantation after two or three cycles of MiCMA.
  • Sixty-two patients underwent autologous stem cell transplantation.
  • CONCLUSIONS: The current results suggested that MiCMA chemotherapy is an effective therapeutic alternative salvage regimen for patients with primary refractory or recurrent NHL.
  • Peripheral blood stem cell transplantation was feasible in virtually all patients, and its outcome was influenced strongly by chemosensitivity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16419074.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BG3F62OND5 / Carboplatin; BZ114NVM5P / Mitoxantrone; X4W7ZR7023 / Methylprednisolone; MiCMA protocol
  •  go-up   go-down






Advertisement